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ABSTRACT
Glycosylation is one of the most abundant post-translational modifications of
proteins. Glycoproteins participate in virtually all aspects of cellular functions.
ST6Gal I is a glycosyltransferase highly expressed by B and T cells. Here, we
interrogated the role of ST6Gal I in viral specific B and T cell immune responses,
as well as examined how loss of this enzyme impacted viral pathogenesis.
First, to understand how loss of ST6Gal I expression impacted viral specific
humoral responses, we infected ST6Gal I-/- mice with influenza virus. We
discovered that loss of ST6Gal I expression results in both reduced influenza
specific antibodies levels and decreased viral-specific antibody secreting cells
numbers. Following influenza infection, mice that received ST6Gal I-/- B cells
showed reduced influenza-specific IgM responses compared to mice that
received wild-type B cells. These experiments demonstrated that the expression
of ST6Gal I by B cells is required for optimal viral-specific humoral response.
We further examined how loss of ST6Gal I expression impacted the antiinfluenza IgA response. We observed that immune ST6Gal I-/- mice displayed
higher viral specific IgA levels and altered sialylation of IgG and IgA, which have
been implicated in a human disease, IgA nephropathy. Moreover, ST6Gal I-/mice exhibited increased immunoglobulin deposition in kidney glomeruli following
influenza infection. These data suggest that ST6Gal I deficiency, together with
influenza infection, may result in the initiation of a kidney disease.
Finally, we examined how ST6Gal I expression regulated CD8 T cell responses.
We discovered that ST6Gal I is differentially expressed during CD8 T cell
activation. To understand its relevance, we infected ST6Gal I-/- mice and
demonstrated that the early expansion of effector T cells was impaired in a cell
intrinsic manner. Moreover, in the absence of ST6Gal I, the differentiation of CD8
iii

T cells skewed towards memory precursor cells, whereas terminal effector cell
expansion was impaired. Mechanistically, we identified delayed surface
expression of IL-2Ralpha on ST6Gal I-/- CD8 T cells due to impaired IL-2/IL-2R
signaling. These studies implicate that ST6Gal I expression enhances early
proliferation of terminal effector CD8 T cells by promoting the rapid surface
expression of IL2Ralpha during acute viral infection.
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CHAPTER I
INTRODUCTION AND OVERVIEW
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1. Adaptive immunity overview
The immune system is comprised of multiple cellular players. These cells
express a variety of cell surface and intracellular molecules, which cooperate in
an elaborate and dynamic network to recognize and eliminate pathogenic
microorganisms. There are two arms of the immune system distinguished
temporally, functionally, and in their antigen specificity. The innate immune
system

is

distinguished

by

the

use

of

pattern

recognition

receptors

(PRRs)(Mogensen, 2009). Cells expressing PRRs recognize and destroy
insulting pathogens expressing pathogen associated molecular patterns
(PAMPs). The innate response consists of effector cells such as granulocytes,
natural killer (NK) cells, and phagocytes and represents the first line of host
defense against invading pathogens, launching the inflammatory response
following infection. In addition, phagocytes engulf pathogens and cellular debris
and subsequently present protein antigens to T lymphocytes to initiate adaptive
immune responses(Bonilla and Oettgen, 2010). Importantly, the innate immune
system differs functionally from the adaptive immune response in that it does not
confer long-term immunity, or memory, to the host. The innate response behaves
identically following re-infection with the same agent. The second arm of the
immune system is the adaptive or acquired immune response. It provides the
second line of defense, often taking days to respond following the onset of
infection. The adaptive immune system is comprised of B and T lymphocytes,
expressing a tremendous variety of antigen recognition receptors that recognize
specific antigen--either unprocessed antigens in the case of B cells or processed
antigen in complex with self-major histocompatibility complex (MHC), in the case
of T cells(Bonilla and Oettgen, 2010; Cooper and Alder, 2006). The orchestration
of B and T cells constitute a highly sophisticated biological response that enables
the host to potentially recognize virtually any pathogenic agent. Following
elimination

of

the

pathogen,

the

adaptive

immune

system

acquires
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immunological memory, which can efficiently and quickly launch pathogenspecific responses to prevent re-infection with the same agents.

1.1 B and T cells
Instructed by environmental cues, pluripotent hematopoietic stem cells in the
bone marrow differentiate into common myeloid progenitors and common
lymphoid progenitors, and further develop into myeloid cells and lymphocytes,
respectively(Cooper and Alder, 2006). In the bone marrow, the commitment to
the B cell lineage is controlled by transcription factors, such as PU.1, IKAROS,
and PAX5(Fuxa and Skok, 2007; LeBien and Tedder, 2008). B cell progenitors
undergo several distinct developmental stages to achieve complete development
to resting naïve B cells and then exit the bone marrow to circulate in the
periphery. Following antigen stimulation, the majority of B cells will proliferate,
differentiate into plasma cells, or enter germinal center reactions following
contact with T-dependent antigens.
T lymphocytes also arise from common lymphoid progenitors in the bone marrow
but must migrate to the thymus for further development, where they reach
maturation under the control of Notch and other transcription factors(Jenkinson et
al., 2006). Before T cells can exit the thymus to seed the periphery, they must
pass strict quality control. After T cells express a functional T cell receptors
(TCR) on their surface, they will go through a process called positive selection,
during which only those T cells that recognize self-MHC receive signals enabling
their survival. T cells also undergo negative selection, where those T cells that
bind to self-MHC with high affinity will be eliminated to prevent autoimmunity.
During development in the thymus, T cells differentiate into two major
subpopulations, distinguished by their surface expression of CD4 or CD8
molecules. CD4 T cells are the master regulators of adaptive immune
3

responses(Zhu and Paul, 2008). Upon contact with cognate antigen in the
context of MHC class II expressed by antigen presenting cells (APCs), which are
dendritic cells, activated macrophages, and activated B cells, naïve CD4 T cells
differentiate into Th1, Th2, or other recently identified subsets. T helper subsets
are characterized by the secretion of specific cytokines, such as IFNγ or IL-4. The
diverse subsets of CD4 helper T cells orchestrate both B cell and T cell response
against a plethora of pathogenic agents. CD8 T cells, also called cytotoxic
lymphocytes (CTLs), can recognize processed peptide presented by MHC class
I, expressed by all nucleated cells(Williams and Bevan, 2007). After a virus
infects host cells, it usurps host protein synthesis machinery to produce viral
protein, and viral peptides will be presented on the cell surface in the context of
appropriate MHC class I. CD8 T cells can recognize MHC I/viral peptide
complex, and kill virally-infected cells by either secreting a pore-forming protein
(perforin), and a series of proteases (granzymes), or up-regulating a tumor
necrosis factor (FasL) to induce apoptosis in the targeted cells. Thus, CD8 T
cells are critical against intracellular pathogen infections and tumors.

1.2 Viral immunity
1.2.1 LCMV
Lymphocytic chriomeningitis virus (LCMV) is a member of the Arenaviridae
family, causing acute or chronic infections of rodents(Buchmeier et al., 1980), the
natural host. LCMV has a bisegmented, negative, enveloped, and singlestranded RNA genome, and the virus replicates systemically within the
host(Fazakerley et al., 1991). It is a well-established virus model for investigating
virus-specific T and B cell responses(Botten et al., 2010). During acute virus
infection, a vigorous viral-specific CD8 T cells response is induced in lymphoid
organs, and functional CD8 T cells are required for virus clearance (Asensio et
al., 1999).
4

1.2.2 Influenza
Influenza virus belongs to Orthomyxoviridae family. It contains a segmented,
negative, enveloped, and single-stranded RNA genome, causing an acute and
contagious pulmonary disease(Cox et al., 2004; Nicholson, 1992). According to
the antigenic differences of nucleoprotein and matrix protein, influenza viruses
are categorized into three types: type A, B, C. Two major viral glycoproteins
hemagglutinin (HA) and neuraminidase (NA) expressed on the virion surface
mediate the binding and entry to target cells and the release of progeny virus
from the infected cell, respectively(Cox et al., 2004). Influenza viruses are
constantly undergoing antigenic mutations to escape from host adaptive
immunity, especially humoral immunity, causing antigenic shift and antigenic drift.
Influenza infection induces robust B cell responses, and vigorous viral-specific
antibody production contributes to virus clearance(Gerhard et al., 1997). In
addition, influenza virus also elicits strong CD4 and CD8 T cells responses in the
lung(Doherty et al., 1997).

2. Glycomics and immunity

2.1 Glycosylation, glycomics, and glycosyltransferase
Glycosylation refers to the generation of different types of glycans or sugars that
are attached to proteins and lipids(Varki., 2009). Glycan biosynthesis occurs
along the protein secretory pathway, predominantly, within the Golgi apparatus.
There are also some other forms of glycosylation that occur in the cytoplasm and
nucleus. There are two types of glycans, and their classification depends on the
nature of their linkage. N-glycans are glycosidically linked to the asparagine
residues of polypeptides; in contrast, O-glycans are linked to serine or threonine
residues of proteins.
5

Glycomics refers to the comprehensive study of total glycan structures of a given
cell or organism，and is referred to as the glycome(Varki., 2009). In parallel with
proteomics, glycomics is becoming a major research field. In fact, the glycome is
far more complicated than either the genome or proteome. Studies have showed
that most proteins and lipids on the surface of cellular membranes, as well as
those of pathogens, are modified with a dense array of glycans, which undergo
variable

and

dynamic

changes

in

the

course

of

development

and

pathogenesis(Cobb and Kasper, 2005; Varki, 2006). Indeed, glycans serve as
linking bridges between cell-cell and cell-extracellular matrix (ECM) and glycans
are recognized by carbohydrate-binding proteins, such as lectins and adhesion
molecules(Alavi and Axford, 2008; Ohtsubo and Marth, 2006). These interactions
allow glycans to participate in virtually all cellular processes that impact health or
disease. Specifically, glycans have been found to regulate protein folding, cell
adhesion, signal transduction, molecular homeostasis, endocytosis, receptor
activation, molecular trafficking, and self/nonself recognition(Ohtsubo and Marth,
2006; Rudd et al., 2001; Varki., 2009).
Glycan biosynthesis occurs in a serially ordered pattern that is primarily
catalyzed

by

glycosyltransferases(Varki.,

2009).

Molecular

cloning

and

sequencing analysis showed that glycosyltransferases are a large enzyme group,
composing up to 2% of the genome. Different from the nucleotide polymerases
that require template to initiate replication, glycosyltransferases elongate glycan
chains independently of template. Glycosyltransferases orchestrate with other
enzymes to partially compete for and add monosaccharides from donor substrate
to acceptor substrates, yielded by previous enzymes(Varki., 2009). This occurs
rapidly and sequentially, extending the linear and/or diverged sugar chain.
Moreover, glycosyltransferases are expressed and regulated in a cell- and/or
stage-specific manner. As a consequence of this regulated expression, a given
cell could readily and rapidly adopt a different glycan pattern on the cell surface
in response to dynamic physiological or pathogenic stimuli. From this
6

perspective, abnormal changes in cellular processes caused by disease, are
likely to generate a different glycan pattern on a given cell during disease
processes(Ohtsubo and Marth, 2006; Varki., 2009).

2.2 Glycosylation and disease
2.2.1 Glycosylation and cancer
Cancer is a class of progressive diseases where clones of a cell show
uncontrolled growth(Hanahan and Weinberg, 2011). These clones may invade
and destroy surrounding tissues, and sometimes metastasize, where the clones
move to other sites in the body through blood or lymph circulation. The
development of cancer, or carcinogenesis, is a multiple-stage process that
includes cancer initiation, promotion, and progression. A wide range of altered
molecular events is found to cause cancer, such as the disruption of cell cycle,
and the dysregulation of intracellular and/or intercellular signaling(Duffy et al.,
2008; Hanahan and Weinberg, 2011).
It has been reported decades ago that the glycosylation pattern changes in an in
vitro mouse transformed fibroblasts(Meezan et al., 1969). Since then, with the
application of more tools and approaches, a deep insight of the crucial roles of
glycans at various stages of carcinogenesis has been gained from intense
experimental investigations. For example, the survival of melanoma and sarcoma
cells in vitro was hampered when treated with N-glycosylation inhibitors (Dricu et
al., 1999; Girnita et al., 2000). This is because inhibition of N-glycosylation leads
to the down-regulation of cell surface insulin like growth factor-1 receptor (IRG1R), which has been shown to be critical for tumor development(Dricu et al.,
1999).

As

a

consequence,

there

is

a

drastic

reduction

of

IRG-1R

autophosphorylation. This case illustrates how altered glycosylation in surface
molecule affects tumor cell proliferation.
7

Glycosylation also regulate other aspects of tumor progression. When tumor cells
are ready to invade adjacent tissues, they detach themselves from each other
and from the extracellular matrix (ECM) and then move to neighboring sites(Duffy
et al., 2008). This occurs through the changes of expression of cell-surface
adhesion receptors and ligands, and the secretion of proteolytic enzymes and
glycosidases that break ECM networks. Tumor cells have been shown to
increase the expression of N-acetylglucosaminyltransferase V (GnT V), which
would upregulate the surface expression of complex β1,6-branched N-linked
glycans(Dennis et al., 2002; Yoshimura et al., 1996). Particularly, increased
modification of β1,6-branched N-linked glycan structure on the E-cadherin
molecule expressing on tumor cell surfaces mediates cell aggregation via
homotypic interactions(Dennis et al., 2002). This results in decreased cell-cell
adhesions, promoting cell detachment and invasiveness(Dennis et al., 2002).

2.2.2 Glycosylation and immune disorders
Abnormal glycomodifications, which can be inherited or acquired, are found to
correlate with a wide spectrum of diseases such as cancer as discussed above.
Altered glycosylation has also been described in several immune disorders,
including Wiskott-Aldrich syndrome (WAS), rheumatoid arthritis (RA), systemic
lupus erythematosus (SLE), congenital disorders of glycosylation (CDG),
leukocyte adhesion deficiency (LAD), and IgA nephropathy (IgAN)(Alavi and
Axford, 2008; Ohtsubo and Marth, 2006). Over the past decades, there is an
increasing body of information regarding the mechanisms of glycan processing
and their role in pathogenesis.

2.2.2.1 Hereditary aberrant glycosylation associated immune diseases
The numbers of diseases correlating with inherited aberrant glycosylation is
relatively low due to either embryonic lethality mutations or limited tools to detect
8

mild syndromes(Alavi and Axford, 2008; Ohtsubo and Marth, 2006). WiskottAldrich syndrome is an X-linked inherited immunodeficiency disorder, caused by
mutations in the Wiskott-Aldrich syndrome protein (WASP) gene(Notarangelo et
al.,

2005).

The

symptoms

of

WAS

include

peripheral

lymphopenia,

thrombocytopenia, small platelet, eczama, and recurrent infections(Imai et al.,
2004; Notarangelo et al., 2005). CD43 is a highly conserved transmembrane
glycoprotein expressed on thymocytes and most hematopoietic cells(Notarangelo
et al., 2005). CD43 has been shown to be involved in the regulation of T cell
migration and immunity(Matsumoto et al., 2005; Onami et al., 2002). Aberrant
glycomodifications of CD43 are present in WAS patients(Higgins et al., 1991;
Piller et al., 1991). As altered glycoforms of CD43 have been shown to be
important for T cell positive selection in the thymus, these changes might lead to
abnormal thymic egress of self-reactive T cells, invoking autoimmune disease
and progressive lymphopenia, which are commonly observed in WAS
patients(Ellies et al., 1996; Khan et al., 2008).

2.2.2.2 Acquired aberrant glycosylation associated immune diseases
Extensive investigations have been carried out to illustrate the role of changes in
the glycosylation of antibodies in autoimmune diseases(Opdenakker et al., 2006;
Varki., 2009). A wealth of evidence suggested that the dysregulation of
glycosylation in IgG contributes to the pathogenesis of the autoimmune disease
rheumatoid arthritis (RA)(Alavi and Axford, 2008; Varki., 2009).

IgGs have

various glycomodifications in the constant domain of Fc region, which can be
terminally decorated by galactose, sialic acid, bi-antennary N-acetylglucosamine,
and fucose(Jefferis, 2005; Kaneko et al., 2006). One key feature of RA is a
significant increase in agalactosylated IgG, which is a good indicator of the
severity of RA symptoms(Gindzienska-Sieskiewicz et al., 2007; Troelsen et al.,
2007). Without the galactosylation of IgG Fc region, it may alter immunogenic
properties, resulting in auto-sensitization and the generation of anti IgG-G0
9

antibody, leading to the formation of immune complexes(Das et al., 2004; Varki.,
2009). Loss of terminal galactose in IgG Fc also expose mannoses, which
normally are not accessible for mannose binding lectin recognition, and may
trigger an inappropriately complement response, generating inflammatory factors
that disturb normal cellular activities(Arnold et al., 2006). The abnormal
glycosylation in IgG Fc also may affect the timing and specificity of interaction
with Fc receptor, thus activating unwanted inflammatory responses that
contribute to RA disease(Kaneko et al., 2006).

2.2.2.3 IgA nephropathy
IgA nephropathy (IgAN) is a common worldwide immune complex-mediated
glomerulonephritis,

characterized

by

IgA

deposition

in

glomerular

mesangium(D'Amico, 1987; D'Amico, 2004). It is often associated with IgG
deposition, hematuria, sometimes with proteinuria, and usually associated with
elevated IgA level in serum(D'Amico, 2004). 20-40% of IgAN patients will develop
renal failure(D'Amico, 2004). Despite the significant morbidity and mortality
caused by IgAN, the root cause of this disease remains unknown. Linkage
studies could not convincingly establish any genes that correlate to IgAN(Gharavi
et al., 2000; Paterson et al., 2007). Studies have shown that IgA1 was
abnormally O-glycosylated in IgAN(Hiki et al., 1995; Mestecky et al., 1993).
Immune complexes containing the abnormally O-glycosylated IgA1 and IgG or
IgA1 autoantibodies against the aberrant IgA1 were also reported in IgAN
patients(Novak et al., 2008). The dysregulated O-glycosylation of IgA1 in IgAN is
now well established. However, the molecular mechanisms causing this
dysregulation and the initiation of the disease process in IgAN remains largely
unknown.
Several groups have developed mouse models for human IgAN, including loss of
uteroglobin, an anti-inflammatory protein, and a genetic knock-in mouse that
10

expresses human Fcα receptor on macrophages/monocytes(Launay et al., 2000;
Zheng et al., 1999). Moreover, a recent study showed that β4GalT-1-deficient
mice displayed most of the pathological and clinical traits of human IgAN, and
therefore it may have utility as a novel animal model to study how aberrant
glycosylation initiates an IgAN-lilke pathogenesis(Nishie et al., 2007).

2.3 Sialyltransferase
Sialic acids (SA) are a group of negatively charged 9-carbon monosaccharides
derived from neuraminic acid. More than 50 naturally occurring SAs have been
discovered(Varki and Varki, 2007). Numerous sialylated glycoconjugates have
been identified, which exhibit remarkable diversity in both different linkages with
other sugar molecules and structurally natural modifications in a cell type and
developmentally modulated style(Varki., 2009). Typically, SAs are found
abundantly attached to the outmost terminal positions of N-glycans, O-glycans
and glycosphingolipids in all vertebrate cell types and throughout all tissues and
body secretions. In addition, SA modifications often change in response to
environmental signals. As a consequence of their tremendous diversity and
terminal location on the cell membrane, SAs have been shown to play a wide
variety of roles in many physiological or pathological processes, particularly in
neural development, pathogen recognition, and immune function(Varki, 2008;
Varki., 2009).
As a subset of glycosyltransferases, sialyltransferases catalyze the transfer of
sialic acid residues from donor substrate CMP-NeuAc to the terminus of
glycoproteins and glycolipids within the reticulum-Golgi biosynthesis factory. To
date, 20 different sialyltransferases have been identified to generate three key
types of sialic acid linkage in mouse and humans. The most abundant sialic acid
linkage is α2,3 linkage and is produced at least by 6 α2,3-sialyltransferases
(ST3Gal

I-VI).

α2,8

sialic

acid

linkages

are

generated

by

6

α2,811

sialyltransferases (ST8Gal I-VI). GalNAc α2,6-sialyltransferases (ST6Gal NAc-IVI) and α2,6-sialyltransferases (ST6Gal I and II) catalyze the addition of α2,6
linked sialic acid to Galβ1,4GalNAc and Galβ1,4GlcNAc, respectively(HarduinLepers et al., 1995; Takashima, 2008).

2.3.1 α 2,6-sialyltransferase family
The Galβ1,4GlcNAc (lactosamine) is a common component at the end of Nglycan chains of glycoproteins. It has been shown that ST6Gal I and II are the
only two sialyltransferases to catalyze the addition of sialic acid to lactosamine to
generate Siaα2-6Galβ1-4GlcNAc (Sia6LacNAc), a structure that is recognized by
several lectins including a plant lectin Sambucas nigra agglutinin (SNA)(Hennet
et al., 1998; Varki, 2008). ST6Gal II shows restricted acceptor substrate
specificity toward oligosaccharides(Takashima, 2008). In addition, it is mainly
expressed in brain and during embryonic development. In contrast, ST6Gal I
exhibits broad substrate specificity toward glycoprotein, glycolipid, and
oligosaccharides(Takashima, 2008). Moreover, ST6Gal I is expressed in many
tissues at relatively low level except lymphoid organs(Takashima, 2008). Both
ST6Gal genes have similar genomic structures. They use physically distinct
promoters and the alternative splicing strategy to generate isoforms from primary
RNA transcripts in different tissues(Wuensch et al., 2000). When P1, one of six
promoters that drives murine ST6Gal I expression, is deleted, mice showed
neutrophillia and eosinophillia, suggesting P1 region might be involved in the
regulation of myelopoiesis(Nasirikenari et al., 2010; Nasirikenari et al., 2006).
However, the functional relevance of these tissue-specific transcript variants is
still not fully understood.
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2.3.2 ST6Gal I and immune regulation
ST6Gal I RNA is highly expressed in hematopoietic cells such as T and B cells,
implicating a physiological role of ST6Gal I in hematopoietic cells(Kitagawa and
Paulson, 1994; Wen et al., 1992). Indeed, ST6Gal I generates the Sia6LacNAc
which serves as the ligand for the mammalian lectin CD22 molecule, which is
exclusively expressed on B cells. CD22 is a transmembrane glycoprotein, which
negatively regulates B cell signaling by recruiting phosphatase SHP-1 to the B
cell receptor to dampen B cell signaling(Nitschke, 2005). When ST6Gal I
knockout mice were generated, these mice displayed impaired B cell responses,
including reduced serum IgM levels, hampered B cell proliferation in response to
IgM and CD40 ligation, and impaired antibodies generation when immunized with
T-independent (DNP-Ficoll) and T-dependent antigens (DNP-KLH)(Hennet et al.,
1998). These studies clearly showed that ST6Gal I played a critical role in B cell
immune responses.
Early studies reported that ST6Gal I-deficient T cells proliferated normally when
stimulated with anti-CD3 antibody in vitro(Hennet et al., 1998). However, a global
gene profiling analysis showed a significant decrease of Stgal1 mRNA after T cell
activation(Comelli et al., 2006; Kaech et al., 2002), suggesting a role of ST6Gal I
in T cell activation. Another study demonstrated that, compared to Th1 and Th17
cells, Th2 CD4 T cells expressed significantly more ST6Gal I, which might
account for reduced galectin-1 binding and subsequent apoptosis, implicating
that ST6Gal I regulated CD4 T cell differentiation(Toscano et al., 2007).
Nonetheless, the in vivo role of ST6Gal I in T lymphocyte immune responses
remains largely unexplored.
On the other hand, ST6Gal I is involved in inflammation regulation. It has been
shown that knockout mice demonstrated significantly enhanced neutrophil and
eosinophil infiltration into peritoneal cavity after intraperitoneally challenge with
thioglycollate(Nasirikenari et al., 2010; Nasirikenari et al., 2006), suggesting a
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regulatory role of ST6Gal I in inflammatory responses. Surprisingly, ST6Gal I
also can contribute to modulating inflammation via differential α2,6-sialylation of
IgG Fc fragment, which may determine the pro- or anti-inflammatory effects of
IgG by regulating its binding to corresponding Fcγ receptors(Kaneko et al., 2006).

2.3.3 ST6Gal I and disease
It has long been appreciated that ST6Gal I expression correlated with
inflammation(Dall'Olio, 2000). It seems that the expression of ST6Gal I, similar to
acute phase proteins, is enhanced upon induced inflammation(Kaplan et al.,
1983). Furthermore, it has been suggested that IL-6 may regulate ST6Gal I
expression, at least the induction of hepatic ST6Gal I (Dalziel et al., 1999). The
increased expression of ST6Gal I during inflammation would generate higher
levels of sialyl α2,6-lactosaminyl terminals, which might serve as decoy biding
sites to prevent incoming pathogens from interacting with host cells that express
surface α 2,6-linked sialic acid for important endogenous recognition. Another
potential function of increased ST6Gal I is that the increased levels of α2,6
sialylation would decrease the numbers of α2,3 sialylated epitopes, which are
preferentially recognized by incoming pathogens(Gagneux and Varki, 1999).
Thus, manipulating the expression of ST6Gal I might serve to combat pathogen.
The increased expression of ST6Gal I has been implicated in diseases such as
colon and breast carcinoma, acute myeloid leukemia, and in some brain tumors
(Dall'Olio and Chiricolo, 2001). Moreover, increased Siaα2,6 Gal levels have
been shown to enhance transformed cell motility and invasiveness in
vitro(Chiricolo et al., 2006; Seales et al., 2005). A recent in vivo study
demonstrated that loss of ST6Gal I affect the integrin signaling pathway, and
consequently favor mammary tumor progression(Hedlund et al., 2008).
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3. B cell activation and differentiation

3.1 B cell subsets and activation
B cells undergo antigen-independent development first in bone marrow and then
in spleen. After complete maturation, some B cells migrate to the marginal zone
and remain there as naïve resident marginal zone (MZ) B cells(Steiniger et al.,
2006). The majority of B cells will go on to circulate to the splenic follicles, and to
other sites, such as the lymph nodes and bone marrow(LeBien and Tedder,
2008). After exposure to cognate antigen, B cells increase in size and start to
proliferate to become B-cell blasts. Those B-cell blasts that synthesize and
secrete antibody are named plasmablasts, and can terminally differentiate into
plasma cells, which secret measurable amounts of immunoglobulin without
proliferation. MZ B cells are unique in their inborn ability to rapidly (within hours)
develop into short-lived plasma cells that secrete immunoglobulin, responding to
antigenic stimuli in the absence of T-cell help(Oliver et al., 1997; Snapper et al.,
1993). In contrast, circulating naïve B cells require two signals to become fully
activated and undergo further differentiation(Bonilla and Oettgen, 2010; Oracki et
al., 2010). The first signal is the antigen-mediated cross-linking of the
immunoglobulin receptor, which activates the intracellular signaling pathway. As
a consequence of this activation, B cells internalize the antigen-BCR complex
and process the antigen to peptides that subsequently conjugates to appropriate
MHC II molecules. These peptide-MHC II complexes then are delivered to the
cell surface. When B cells interact with previously activated CD4 T cells specific
for this peptide-MHC II complex, the CD4 T cells provide direct cell-cell contact
(signal 2) to fully activate B cells. Consequently, the activated B cells can
undergo proliferation and differentiation to plasma cells to elicit extra-follicular
responses. Alternatively, fully activated B cells enter germinal centers. Germinal
centers are special sites within the follicle, where B cells change from the
generation of IgM and IgD to other isotypes, such as IgA, IgG, and IgE through
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rearrangement of gene segments that encode the constant region of
immunoglobulin heavy chain(Stavnezer et al., 2008). Meanwhile, B cells also
undergo rounds of proliferation to accumulate point mutations in the variable
chains of the immunoglobulin heavy and light chain, a process called somatic
hypermutation,

which

results

in

the

production

of

antigen-specific

immunoglobulins with high affinity(Peled et al., 2008). B cells eventually develop
into long-lived plasma cells (LLPCs), or memory B cells (MBCs) expressing highaffinity, and class-switched surface immunoglobulin receptors. These cells exit
the germinal center approximately two weeks after immunization(Bonilla and
Oettgen, 2010; Shapiro-Shelef and Calame, 2005).

3.2 B cell memory
B cell memory consists of two cellular components, including MBCs and
LLPCs(Kurosaki et al., 2010; LeBien and Tedder, 2008). Both cell types provide
long-term immunity. Generated in the germinal center, MBCs retain high affinity
surface BCR and co-express the mature B cell markers B220 and
CD19(Kurosaki et al., 2010). After exit from the germinal center, MBCs distribute
throughout the body. MBCs can persist in the absence of antigenic stimulation
and do not secrete immunoglobulin(Kurosaki et al., 2010). However, MBCs can
more rapidly differentiate into plasma cells and produce antigen-specific antibody
to contain an infection compared to naïve B cells when re-encounter the
pathogenic agent and in the presence of CD4 T cell help. In contrast, LLPCs are
terminally differentiated B cells with a long lifespan that constantly secrete high
affinity antibodies and persist in the absence of antigen or additional
proliferation(Bonilla and Oettgen, 2010). Once developed from intrafollicular B
cells in the germinal center, LLPCs express the homing chemokine receptors
CXCR3, CXCR6, and integrin α4β1, enabling LLPCs to migrate to bone marrow,
where they reside for the rest of their life(Kunkel and Butcher, 2003).
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4. CD8 T cell activation and differentiation

4.1 Effector and memory CD8 T cell subsets are heterogeneous
Antigen-inexperienced, naïve CD8 T cells egress from thymus and populate
secondary lymphoid organs. During an infection, naïve CD8 T cells that interact
with specific peptide-MHC I complex, costimulatory signals, and cytokines,
become activated and undergo proliferation and differentiation into effector CD8
T cells(Lefrancois and Obar, 2010; Smith-Garvin et al., 2009). During
differentiation, they acquire effector cytotoxic activities, changes in adhesion
molecules and chemokine receptor expression, which allows them to migrate to
sites of infection. About one week following acute infection, antigen-specific CD8
T cell numbers peak, then undergo a significant attrition or contraction, where
only 5-10% of the cells survive and become long-lasting memory cells. Memory
CD8 T cells are long-lived, maintaining stable numbers via homeostatic turnover
that is IL-15 dependent. Memory CD8 T cells remain in a resting state with low
cytotoxicity, however, they are able to rapidly expand and regain effector
functions following re-exposure to the same pathogen(Cui and Kaech, 2010;
Lefrancois and Obar, 2010; Rutishauser and Kaech, 2010).
Only a small number of effector cells survive to become memory cells. However,
the phenotypic and transcriptional traits embedded in the effector cells, which
direct them to differentiate either into end-stage effector cells, or into memory
cells, are largely unknown. Recent work to compare the global gene expression
profiles of naïve, effector, and memory cells identified a few genes that are
distinctly expressed at different stages of CD8 T cells development(Kaech et al.,
2002; Schluns et al., 2000). First, IL-7Rα expression was identified as being
differently expressed in effector subsets(Kaech et al., 2002). Together with the
identification of surface marker killer cell lectin-like receptor G1 (KLRG1), which
also distinguished effector populations, a new classification emerged where
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effector subsets could be identified and used to study heterogeneity within
effector CD8 T cells(Joshi et al., 2007; Sarkar et al., 2008). It is now established
in several mouse infection models that during a primary infection, naïve CD8 T
cells expand and differentiate into two subsets of effector cells, one termed shortlived effector cells or SLECs (KLRG1hi IL-7Rαlo), also known as terminal
effectors, and these cells account for the majority of effector cells. SLECs have a
shortened lifespan, proliferate earlier and more extensively, and fade after
pathogen clearance. The other subset is called memory precursor effector cells
or MPECs (KLRG1lo IL-7Rαhi), and have higher capacity to give rise to memory
cells(Joshi et al., 2007; Kaech et al., 2003).
The memory CD8 T cell population is also heterogeneous. Memory CD8 T cells
that show high expression of CD62L and CCR7 are defined as central memory
cells (Tcm)(Cui and Kaech, 2010). These cells are preferentially localized in
lymphoid organs, display low cytotoxic activity ex vivo, and have a higher
capacity to proliferate and generate IL-2(Cui and Kaech, 2010; Rutishauser and
Kaech, 2010). The other memory CD8 T cell subpopulation is termed effector
memory CD8 T cells (Tem). These Tem, preferentially reside in non-lymphoid
organs, maintain ex vivo lytic activity, undergo less homeostatic renewal, have a
more limited lifespan, and lack expression of lymph node homing molecules such
as CD62L and CCR7 (Hikono et al., 2007; Wherry et al., 2003).

4.2 Regulation of CD8 T cell differentiation
How do different populations of effector and memory CD8 T cells arise during a
pathogen infection? A recent study demonstrated that the fate of naïve CD8 T
cells is not predetermined: an individual naïve precursor CD8 T cell can develop
into heterogeneous effector and memory CD8 T cell populations. In this study,
single cell transfer of an antigen-specific naïve CD8 T cell into a recipient mouse,
followed by challenge with Listeria monocytogenes, showed that different effector
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and memory cell subsets could develop from a single precursor CD8 T cell. This
study suggested the concept of “one naïve cell, multiple fate” regarding CD8 T
cell development(Stemberger et al., 2007). But when and how the cell fate
decision was made still remain controversial. Several models have been
proposed to explain the developmental relationship of the effector and memory T
cell, which differentially highlight the role of extrinsic factors, such as quality,
duration, or quantity of antigenic stimulation, or the intrinsic factors in CD8 T cells
themselves, such as the differentiation status(Chang et al., 2007; Kaech and
Ahmed, 2001; Sarkar et al., 2008; Williams and Bevan, 2007).
What determines the effector versus memory differentiation decision? It has been
shown that many factors influence the establishment of heterogeneity of effector
and memory CD8 T cell, such as the duration of infection, time of recruitment of
naïve CD8 T cells during infection, sufficiency of inflammatory signals, and
tissue-specific microenvironment(D'Souza and Hedrick, 2006; Hikono et al.,
2007; Joshi et al., 2007; Rutishauser and Kaech, 2010). These different signals
may synergize with each other to drive T cell activation, proliferation, and
differentiation(Harty and Badovinac, 2008; Mescher et al., 2006). It seems that
activated CD8 T cells will automatically undergo an effector cell program, as both
SLEC and MPEC possess lytic activity(Joshi et al., 2007). In particular, recently it
has been reported that the strength of IL2-IL-2R signaling is strongly correlated
with the cell fate of effector cells(Kalia et al., 2010; Obar et al., 2010; Pipkin et al.,
2010). In the presence of strong IL-2 signals or with a higher, early expression of
IL-2 receptor α chain, cells rapidly acquire effector functions such as perforin and
granzyme B expression, but show a reduced capacity to gain MPEC marker
expression. On the other hand, with weak IL-2 inputs or low early expression of
IL-2Rα, cells tend to undergo incomplete effector differentiation and obtain more
features of memory cells(Kalia et al., 2010; Pipkin et al., 2010). These studies
suggested that the dose of IL-2 signaling, or the ability to receive IL-2 input
(surface expression level of IL-2Rα), might push early activated CD8 cells to
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favorably differentiate towards terminal effector cell or memory cells. Other
inflammatory cytokines, such as IL-12 and IFNα, also seem to augment SLEC
development during pathogen infection(Joshi et al., 2007).
As activated CD8 T cells are exposed to numerous signals during infection, how
these exogenous signals are transmitted to cells and converted into
transcriptional regulators that initiate and promote effector versus memory cell
fate differentiation is a critical question. The gene expression levels of a range of
transcription factors, such as Id2, Gfi-1, Blimp-1, and two highly homologous Tbox proteins T-bet and Eomesdermin, changes as the naïve CD8 T cell
differentiates into effector cells. This suggests that transcriptional regulation plays
an important role in CD8 T cell differentiation(Kaech et al., 2002; Rutishauser
and Kaech, 2010). In particular, the expression of T-bet or Blimp-1 was found to
be elevated in short-lived effector CD8 T cells relative to memory precursor
cells(Joshi et al., 2007; Kallies et al., 2009; Rutishauser et al., 2009). In addition,
T-bet or Blimp-1-deficient CD8 T cells preferentially developed into memory
precursor cells, demonstrating their importance in the early steps of CD8 T cell
differentiation.
Within the cell, how exactly the downstream regulators of different exogenous
signals cooperate to determine early CD8 T cells differentiation remains unclear.
Different signals might take charge at different stages of development. The TCR
signal is absolutely needed for the initiation of T cell activation and differentiation,
although not necessarily memory differentiation as has been shown in several
studies of lymphopenia induced memory(Cho et al., 2000; Hamilton et al., 2006;
Lee et al., 2011). The extent of the activated CD8 T cell response is presumably
enhanced by costimulatory signals(Smith-Garvin et al., 2009). To some extent, it
seems that the combination of inflammatory cytokines, which probably represent
certain cellular- or tissue- and/or stage- specific environment signals, tip the T
cell developmental direction according to environmental cues. Downstream
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transcriptional regulators that become activated following TCR signals might first
open up and expose critical gene loci, which are targets for other downstream
regulators of additional signals. Consequently, the expression level of specific
transcription factors such as T-bet and other effector molecules might be
altered(Letimier et al., 2007; Placek et al., 2009). Therefore, the activated CD8 T
cells adopt either the terminal effector or SLEC differentiation or the MPEC
program.

5. Research focus
The goal of my dissertation study was to extensively investigate the role of α2,6
sialylation, catalyzed by the glycosyltransferase ST6Gal I in viral T and B cell
immunity. I addressed several questions. What role does ST6Gal I expression
play in antiviral humoral responses? How does ST6Gal I deficiency affect the
generation of viral-specific antibody secreting plasma cells, long-lived plasma
cells, and memory B cells? What role does ST6Gal I expression by B cells play
in the antiviral homoral response?
Additionally, we examined how loss of α2,6 sialylation affected the generation of
viral-specific IgA. How does sialylation of IgG and IgA change in the absence of
ST6Gal I expression? Additionally, we examined the pathogenic outcome in
ST6Gal I-deficient mice of IgA and IgG deposition in the kidney.
Finally, we probed the role of ST6Gal I in virus-specific CD8 T cell responses.
What is the relevance of the differential expression of ST6Gal I in CD8 T cell
subpopulations following viral infection? How does loss of ST6Gal I affect the
differentiation of effector CD8 T cells during acute viral infection? We determined
the mechanisms underlaying differences in CD8 T cell differentiation in the
absence of ST6Gal I. our studies revealed a role for ST6Gal I expression in
regulating IL-2 receptor signaling during effector CD8 T cell differentiation.
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CHAPTER II
THE GENERATION OF INFLUENZA-SPECIFIC HUMORAL
RESPONSES IS IMPAIRED IN ST6GAL I-DEFICIENT MICE
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Abstract
Post-translational modification of proteins, such as glycosylation, can impact cell
signaling and function. ST6Gal I, a glycosyltransferase expressed by B cells,
catalyzes the addition of α-2, 6 sialic acid to galactose (Siaα2-6Gal), a
modification found on N-linked glycoproteins such as CD22, a negative regulator
of B cell activation. We show that SNA lectin, which binds Siaα2-6Gal, shows
high binding on plasma blasts and germinal center B cells following viral
infection, suggesting ST6Gal I expression remains high on activated B cells in
vivo. To understand the relevance of this modification on the antiviral B cell
immune response, we infected ST6Gal I-/- mice with influenza A/HKx31. We
demonstrate that the loss of ST6Gal I expression results in similar influenza
infectivity in the lung, but significantly reduced early influenza-specific IgM and
IgG levels in the serum, as well as significantly reduced numbers of early viral
specific antibody-secreting cells (ASCs). At later memory time points, ST6Gal I-/35

mice show comparable numbers of IgG influenza-specific memory B cells and
long-lived plasma cells, with similarly high antiviral IgG titers, with the exception
of IgG2c. Finally, we adoptively transfer purified B cells from WT or ST6Gal I-/mice into B cell deficient (µMT-/-) mice. Recipient mice that received ST6Gal I-/- B
cells demonstrated reduced influenza-specific IgM levels, but similar levels of
influenza-specific IgG, compared to mice that received WT B cells. These data
suggest that a B cell intrinsic defect partially contributes to the impaired antiviral
humoral response.

Introduction
Humoral immunity is characterized by prolonged antibody production, even after
resolution of infection, in stark contrast to the T cell response, where effector T
cell function is relatively short-lived. Antibodies, by neutralizing or opsonizing free
extracellular pathogens, serve as a critical first-line defense against infection.
Humoral immunity is comprised of pre-existing antibody produced by antibody
secreting cells (ASCs) termed long-lived plasma cells (LLPCs), as well as a
population of memory B cells (MBCs) that can differentiate following antigenic
stimulation into plasma cells (Kalia et al., 2006; Slifka and Ahmed, 1996; Slifka
and Ahmed, 1998; Slifka et al., 1998).
The enzyme ST6Gal I is a glycosyltransferase highly expressed by B and T cells
that synthesizes the glycan sequence α2,6 sialic acid linked to galactose (Siaα26Gal) (Hennet et al., 1998). This structure is typically found on N-linked glycans
of glycoproteins, such as the mammalian lectin CD22, a transmembrane
glycoprotein expressed by B cells that has high specificity for (Siaα2-6Gal).
CD22 has been shown to be a negative regulator of B cell signaling by recruiting
SHP-1 to the BCR, thus attenuating signals via the BCR (Collins et al., 2006;
Hennet et al., 1998; Nitschke, 2005). The plant lectin Sambucas nigra agglutinin
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(SNA) binds the product of ST6Gal I, Siaα2-6Gal, so SNA lectin binding can be
used as an indicator of ST6Gal I expression and/or activity (Hennet et al., 1998).
ST6Gal I null mice were initially described several years ago (Hennet et al.,
1998). These mice demonstrate normal T cell activation to anti-CD3 cross-linking
in vitro, but defective BCR signaling in vitro, and reduced antibody production
following immunization with T-independent and T-dependent antigens (DNPFicoll or DNP-KLH) in vivo (Hennet et al., 1998). However, despite indications
that B cell immune function may be compromised in these mice, as well as
evidence that addition of cytokines could abrogate in vitro B cell proliferation
differences, no studies have documented whether or not protective antibody and
memory B cell responses are compromised in these mice when exposed to
pathogenic microorganisms such as live viral infection.
In this study, we have compared the outcome of influenza viral infection of wild
type or ST6Gal I deficient mice. The haemagglutinin (HA) glycoprotein plays a
key role in influenza pathogenicity and is involved in host-cell recognition
(Horimoto and Kawaoka, 2005). First, we show that effective replication of
influenza A/HKx31 (Orthomyxoviridae, Influenza A) does occur in the lungs of
ST6Gal I-/- mice, however these mice demonstrate defective early influenzaspecific B cell responses. Next, we determine that expansion of CD4 and CD8
influenza-specific T cell numbers in the lung and lymph nodes is normal in
ST6Gal I-/- mice. Further, we demonstrate similar overall numbers of influenza
specific IgG MBCs and LLPCs, though we note both a reduction in serum levels
of influenza specific IgG2c and IgG2c producing LLPCs in the bone marrow.
Finally, we demonstrate an impaired influenza specific IgM response in B cell
deficient mice that receive ST6Gal I-/- B cells, suggesting that a B cell intrinsic
defect partially contributes to the impaired humoral response.

Overall, our

findings suggest that lack of ST6Gal I expression appears to prominently impair
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the generation of a viral specific humoral response, but plays a lesser role in
influenza-specific memory.

Materials and methods

Mice and immunizations
ST6Gal I deficient mice were generated by J. Marth and obtained from the
Consortium for Functional Glycomics and bred in-house (Hennet et al., 1998).
C57BL/6 female mice and B6.129S2-Igh-6tm1Cgn/J (µMT-/- mice) were purchased
from The Jackson Laboratory (Bar Harbor, ME). Mice were maintained under
specific pathogen-free conditions at the University of Tennessee in accordance
with university IACUC guidelines and used at 6-12 weeks of age. Anesthetized
mice were intra-nasally infected with 106.8 EID50 influenza A/HKx31 in 30 µl PBS
as previously described (Li et al., 2006; Sangster et al., 2003). mMT-/- mice were
primed with 107.4 EID50 influenza A/HKx31 i.p.

Tissues harvest and flow cytometry
At specified time points (day 7, 10, > 40 post-infection), animals were sacrificed
and tissues harvested for viral titer (lungs only), immunofluorescence, or isolation
of lymphocytes. For isolation of lymphocytes from lungs, lungs were perfused
with 5 ml cold PBS before removal and processed as previously described
(Masopust et al., 2006). Single cell suspensions were stained with mAbs
purchased from BD Pharmingen (CD4, CD8, CD44, B220, CD138, FAS, GL7,
IFNg and TNFa), Vector Labs (SNA and PNA lectins), or Southern Biotech (IgD).
Intracellular cytokine staining was assayed on cells from spleen, lung, and
MedLN. All samples were run on a FACSCalibur (BD Biosciences). All data were
analyzed with FlowJo software (Tree Star). Unpaired student t tests were
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performed to determine statistical significance with *denoting p<.05 ** denoting
P<0.01, and *** denoting P<0.001.

Immunofluorescence
MedLNs were removed from mice on day 7 p.i. and frozen in OCT at –80oC. The
frozen tissues were cut at 8-µm thickness, thaw-mounted onto slides, air dried
and fixed in cold acetone for 10 minutes. The sections were then blocked with
3% BSA and stained for germinal centers with PNA-FITC (Vector Laboratories),
anti-B220-PE, and/or GL7-FITC (BD Pharmingen) as indicated. After staining,
sections were washed with PBS, mounted using Vectashield mounting medium
(Vector Laboratories), and analyzed using a laser scanning confocal microscope
(Leica SP2).

Influenza viral titer determination
Lungs were collected on indicated days post-infection and homogenized in
Hanks media with 0.1% BSA (GIBCO). Eight replicates of the homogenized lung
were serially diluted tenfold across 96-well U-bottom plates in 1xMEM with 0.3%
BSA,

1µg/ml

Trypsin

TPCK-treated

(Worthington),

penicillin

(100IU/ml),

streptomycin (100 µg/ml), and 5% FBS. The titrated lung samples were added to
serum-free MEM MDCK cell monolayer prepared in 96-well tissue culture plates
and incubated for 48h at 37°C and 5% CO2. Wells that were positive for viral
growth were identified by testing supernatants for hemagglutinating activity using
0.5% chicken red blood cells.

ELISPOT assay to detect influenza specific ASCs
A preparation of concentrated viral particles was disrupted for 10 min at room
temperature in a 1:10 dilution of disruption buffer (0.5% Triton X-100, 0.6 M KCl,
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and 0.05 M Tris-HCl, pH 7.5) in PBS, further diluted in PBS, and plated at 1 μ
g/well in nitrocellulose-bottomed 96-well Multiscreen HA filtration plates
(Millipore, Bedford, MA). After overnight incubation at 4°C, plates were washed
with PBS, and blocked with BCM containing 10% FBS. Plates were emptied by
flicking, and cell suspensions (including resuspended cells from 96-well MBC
assay plates) were added in volumes of approximately 100 μ l/well. After
incubation for 3-4 h at 37°C in a humidified atmosphere containing 5% CO2,
plates were thoroughly washed with PBS alone and PBS containing 0.1% Tween
20. Alkaline phosphatase-conjugated goat anti-mouse IgG, IgM, or IgA (Southern
Biotechnology, Birmingham, AL) diluted to 2 μg/ml in PBS containing 5% bovine
serum albumin was added (100 μ l/well), and the plates were incubated
overnight at 4°C. The plates were then washed extensively with PBS alone and
PBS containing 0.1% Tween 20, including washing the underside of the
nitrocellulose filters. Spots were developed at room temperature by the addition
of 1 mg/ml of 5-bromo-4-chloro-3-indolyl phosphate (Sigma, St. Louis, MO) in
diethanolamine buffer (10% diethanolamine, 0.1 M NaCl, 5 mM MgCl2, and 0.1 M
Tris-HCl, pH 9.5), 100 μl/well. After spot development, plates were washed with
PBS and dried, and spots representing individual ASCs were counted using an
Olympus SZX9 stereozoom microscope.

Memory B cell assay
Influenza-specific MBC frequencies were determined by a previously described
LDA based on in vitro stimulation of MBC to differentiate into ASCs (Joo et al.,
2008; Li et al., 2006). Briefly, two-fold dilutions of cells were incubated in 96-well
tissue culture plates (routinely 12 wells per dilution), together with 106 irradiated
(3000 rad) syngeneic naïve spleen cell feeders plus b-propiolactone-inactivated
HKx31 (Charles River, Wilmington, MA). After incubation, cells in each well were
transferred to ELISPOT plates for the enumeration of influenza-specific IgG
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ASCs. Pre-existing virus-specific ASC numbers at the time of sampling were
determined by direct ex vivo ELISPOT assay. After in vitro MBC activation and
ELISPOT analysis, individual wells were scored positive for virus-specific MBC if
progeny ASC numbers were greater than twice the mean pre-existing ASC. The
virus-specific MBC frequency was calculated from the number of negative wells
per cell dilution by extrapolation to the dilution that gave 37% negative wells (Joo
et al., 2008). Linearity between the proportion of negative cultures and the input
cell dose indicated direct measurement of MBC. No influenza-specific IgG ASCs
were detected after in vitro stimulation of lymphocytes from naïve mice or from
mice infected i.n 8 wk previously with an unrelated virus.

B cell transfer and ELISA
MACS B220 beads (Miltenyi Biotech) were used for purification of B cells
according to the manufacturer’s instructions. Purity of B220+ B cells was 95%
determined by FACS. 2x107 B220+ spleen cells were adoptively transferred into
individual primed µMT deficient mice i.v. followed by infection with influenza i.n.
24 hrs later. For serum antibody determination by ELISA, plates were coated with
purified, detergent disrupted influenza A/HKx31 virus (0.5µg/well) and incubated
at 4°C overnight. Plates were washed with PBS-Tween20 (0.05%), blocked with
PBS/FBS (3%), and washed again. Serial three-fold serum dilutions were
prepared in PBS-Tween20 (0.05%)-BSA (0.5%). The plates were incubated at
RT 4 h or overnight at 4°C, then washed thoroughly. Plate-bound secreted Abs
were detected using alkaline phosphatase-conjugated goat anti-mouse Abs with
specificity for IgM, IgG, IgG1, IgG2b, IgG2c or IgG3 (Southern Biotechnology,
Birmingham, AL) diluted in PBS-BSA (1%). After 4 h incubation at RT, plates
were washed extensively, and color development with p-nitrophenyl phosphate
(Sigma) in diethanolamine buffer was read at 405 nm using a Synergy2 MultiDetection Microplate Reader (BioTek Instruments, Inc.). The virus-specific serum
Ab titer is expressed as the reciprocal of the highest dilution giving an
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absorbance value more than twice that for simultaneously titrated samples from
naïve mice.

Results

SNA binding is high on naïve and in vivo activated B cells
The plant lectin SNA preferentially binds a2-6-linked sialic acids and previous
reports have demonstrated high SNA binding on naïve lymphocytes that is
abrogated in lymphocytes lacking ST6Gal I expression (Hennet et al., 1998).
Gene expression studies comparing naïve B cells to in vitro activated B cells
revealed that ST6Gal I expression remains high on activated B cells (Comelli et
al., 2006).
We examined SNA lectin binding by flow cytometry on B cells following in vivo B
cell activation (Figure 2.1). We observed that on day 8 following viral infection,
B220+ CD138+ plasma blasts remain SNA high similar to B220+ IgD+ naïve B
cells in uninfected mice. Additionally, on day 15 post-infection, B220+, Fas+, IgDlo
germinal center B cells also show high SNA lectin binding (Figure 2.1).

Impaired generation of influenza specific humoral responses in ST6Gal I
deficient mice
To examine the functional relevance of this modification for antiviral humoral
responses, we obtained ST6Gal I null mice. ST6Gal I-/- mice develop normally
and show a normal lymphoid compartment and architecture (Hennet et al., 1998;
Martin et al., 2002).

However, B cells from ST6Gal I-/- mice show impaired

proliferation in vitro to anti-IgM, anti-CD40, and LPS stimulation that can be
rescued by the addition of IL-4, or gene ablation of CD22 (Collins et al., 2006;
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Grewal et al., 2006; Hennet et al., 1998). These mice also show defective Tdependent

and

T-independent

humoral

responses

to

hapten-protein

immunization. Previous studies examining antibody responses following viral
infection

have

sometimes

contrasted

with

results

using

hapten-protein

immunizations (Kawabe et al., 1994; Whitmire et al., 1999). We infected ST6Gal
I-/- mice with influenza A/HKx31 and serially bled them to determine influenzaspecific IgM and IgG by serum ELISA (Figure 2.2A). We observed ~10-fold
reductions and ~5-fold reductions in the levels of influenza-specific IgM and IgG,
respectively on day 7 p.i. (Figure 2.2A). Analysis of IgG isotypes on day 7 p.i.
revealed that all isotypes were significantly reduced compared to wild type mice,
with IgG3 and IgG2c showing the most impairment of the IgG isotypes (3- and 7fold, respectively) (Figure 2.2B). By day 14 p.i., influenza-specific IgG was similar
comparing wild-type and ST6Gal I-/- mice, while influenza-specific IgM still
remained impaired.
One possible explanation for the differences observed could be aberrantly
glycosylated antibodies are preferentially scavenged in vivo by lectin bearing
macrophages (Onami et al., 2002). We determined whether ST6Gal I-/- mice are
defective in the generation of viral specific plasma cells (Figure 2.2C).
Examination of influenza-specific ASCs by ELISPOT in the CLN, MedLN, and
spleen show significantly reduced numbers at day 7. Influenza-specific IgM
producing ASCs showed the most impairment, especially in the spleen.
Influenza-specific IgA producing ASCs were reduced, but the reduction was not
statistically significant (Figure 2.2C). These results show that the reduced serum
levels of antiviral antibodies are likely not the effect of preferential scavenging by
macrophages, but rather a defect in the generation of the humoral immune
response.
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Germinal centers of ST6Gal I-/- mice do not bind GL7
To determine if any differences in germinal center formation are present in
ST6Gal I-/- mice, we performed immuno-staining in the lymph nodes. Our
analysis of the MedLN by immuno-fluorescence on day 7 p.i. revealed that
germinal center B cells in ST6Gal I-/- mice show no expression of the germinal
center marker GL7, but show high binding by the PNA lectin (Figure 2.3A). These
data are consistent with results demonstrating that the monoclonal antibody GL7
shows specificity for a sialylated glycan epitope expressed on germinal center B
cells (Naito et al., 2007). FACS analysis of lymphocytes from the CLN of these
mice gating on IgDloB220+ cells showed similar percentages and numbers of GC
cells as measured by expression of germinal center markers Fas and PNA, and
confirmed loss of GL7 binding (Figure 2.3B,D). We also noted that the MFI of
PNA binding was significantly higher in ST6Gal I-/- GC cells compared to WT
(MFI = 1178 vs 549). The frequencies of total plasma cells (CD138+B220+) were
reduced in ST6Gal I-/- mice, consistent with the reduction in viral specific ASCs
and as expected, showed no binding of the SNA lectin (Figure 2.2C and 2.3C).

Productive infection and replication of influenza in ST6Gal I-/- mice
Entry of influenza virus, as well as the productive infection and replication in lung
epithelial cells is dependent on sialic acid modification of glycoproteins.
Productive

influenza

infection

in

humans

depends

specifically

on

sialyloligosaccharides containing terminal N-acetyl sialic acid linked to galactose
by an α2,6-linkage, while in mice the data suggests α2,3-linked sialic acids are
important (Hatakeyama et al., 2005; Ibricevic et al., 2006). Influenza viral titers
were determined in the lungs of mice infected with A/HKx31 (Figure 2.4). We
confirm that similar to wild-type mice, lungs from ST6Gal I-/- mice become
productively infected with influenza A/HKx31 and show comparable viral titers at
day 3 and 5 p.i. By day 7 p.i., we see a trend towards higher viral titers in the
lungs of ST6Gal I-/- mice, which coincides with the early impairment of viral
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specific antibody responses observed in these mice. However, this difference is
not statistically significant (p=.07) and by day 10 virus was cleared by both wildtype and ST6Gal I-/- mice. These results extend the findings in a recently
published report showing several human influenza A viruses are able to
productively infect the respiratory tract of mice lacking ST6Gal I expression
(Glaser et al., 2007).

Viral specific CD4 and CD8 T cells in the lungs and MedLN
Since T cells also express ST6Gal I, we enumerated influenza-specific T cells
isolated from the lungs or draining nodes (MedLN) of wild-type or ST6Gal I-/- mice
on day 10 using CD4 specific (NP311-325) or CD8 specific (NP366-374)
peptides performing intracellular cytokine staining to detect IFNg (Crowe et al.,
2006). ST6Gal I-/- mice generate similar numbers of viral specific CD4 and CD8 T
cells in the lung and MedLN, show similar co-production of TNFa and IL-2, and
show similar numbers of CD44high CD4 and CD8 T cells in these tissues (Figure
2.5 and data not shown). However, we did note reduced numbers of viral specific
CD8 T cells in the spleen on day 10 consistent with our observations of reduced
viral specific T cells following LCMV infection in these mice.

Viral specific memory B cell responses
ST6Gal I-/- mice control influenza infection by day 10, despite impaired influenza
specific humoral responses (Figure 2.4). The strong antiviral T cell responses in
the lungs of these mice likely contribute to this effective viral clearance. Immune
ST6Gal I-/- mice show high levels of class switched IgG antibody; however, a
significant reduction in serum levels of IgG2c was observed, supported by a
significant reduction in frequencies of influenza-specific IgG2c producing LLPCs
in the bone marrow (Figure 2.6A,B). Examination of MBCs in the spleen and
MedLN reveal comparable frequencies of total influenza-specific IgG MBCs
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(Figure 2.6C). These results clearly indicate that with the exception of the
reduced IgG2c levels, immune ST6Gal I-/- mice generated similar high titers of
antiviral specific antibody.

B cell expression of ST6Gal I is required to generate optimal levels of viral
specific IgM
Our data indicate that ST6Gal I-/- mice are able to generate strong antiviral
humoral memory despite early impairments in the generation of the viral specific
humoral response (Figures 2.2 and 2.6). To determine whether it is the
expression of ST6Gal I by B cells alone that results in impairment of the early
antiviral IgM and IgG response, we transferred purified naïve B cells from either
wild-type or ST6Gal I-/- mice into primed B cell deficient µMT-/- mice. Recipient
mice were intra-nasally infected with influenza, and serially bled to determine
influenza specific antibody levels. Mice that received ST6Gal I-/- B cells show
impaired influenza specific IgM levels, but similar viral specific IgG (Figure 2.7).
These data argue that the observed impairment in production of viral specific IgM
in ST6Gal I-/- mice is likely B cell intrinsic, however the impairment in early
production of viral specific IgG is not B cell intrinsic. Thus, expression of ST6Gal I
by B cells, at least in part, is required for normal antiviral humoral immunity.

Discussion
In this report, we have evaluated the influence of post-translational modification
of glycoproteins on the immune response to influenza virus infection. Changes in
the post-translational modification of glycoproteins during immune responses
have been reported for decades, but their functional importance remains obscure
(Baum et al., 1996; Galvan et al., 1998b; Harrington et al., 2000; Kosco et al.,
1988; London et al., 1978; London and Horton, 1980; Onami et al., 2002;
Schrader et al., 1982). We demonstrate that in contrast to observations with PNA
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lectin binding which changes during activation/differentiation B cells, naïve and
activated B cells in vivo show similar high binding of SNA (Figure 2.1). This
supports recently published data showing that ST6Gal I gene expression does
not change following B cell activation in vitro (Comelli et al., 2006). Using ST6Gal
I-/- mice, which lack the ability to catalyze the addition of α2,6 sialic acids to Nlinked glycoproteins, we investigated the role of this modification on the
generation of an influenza-specific humoral response. Serum levels of influenzaspecific antibodies in these mice are reduced early in the immune response, with
influenza-specific IgM responses showing the greatest impairment (Figure 2.2A).
These data are supported by reductions in the frequencies of viral specific
plasma cells, suggesting that the impaired viral specific antibody levels are likely
a result of altered generation of short-lived viral specific plasma cells, and not a
result of preferential scavenging of antibodies lacking α2,6 sialic acids. (Figure
2.2C and 2.3C). Additionally, ST6Gal I-/- mice show no differences in influenza
viral replication in the lungs, so the reduced antibody levels are not due to
reduced viral load or antigen availability in these mice (Figure 2.4). We did
observe comparable influenza-specific CD4 and CD8 T cell responses in the lung
and draining lymph nodes of these mice, and this most likely explains why
ST6Gal I-/- mice are able to control and clear influenza viral infection in the lungs
by day 10, similar to wild-type mice (Figure 2.5). Despite significant impairments
in the generation of an early antiviral humoral response, ST6Gal I-/- mice are able
to generate potent antiviral humoral immunity, with high levels of class switched
IgG antibodies by day 14 and memory time-points (Figure 2.2A, and Figure 2.6).
This is the first reported analysis of antiviral immune responses in ST6Gal I-/mice.
To determine whether the observed impairment of antiviral humoral responses
were B cell intrinsic, we adoptively transferred ST6Gal I+/+ or -/- B cells into primed
B cell deficient µMT-/- mice (Figure 2.7). Primed mice were used to ensure
adequate CD4 T help in these mice. The antiviral IgM response to infection was
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substantially impaired in mice that received ST6Gal I-/- B cells. However, the
antiviral IgG response was similar compared to mice that received wild-type B
cells. These results suggest that the defective antiviral IgM response observed in
ST6Gal I-/- mice is likely B cell intrinsic. While we must be cautious with our
interpretations of antiviral responses in B cell deficient mice due to known
alterations in lymphoid architecture, the results raise the possibility that subtle
defects in an additional cell compartment in ST6Gal I-/- mice may contribute to
the delayed antiviral IgG response. Future studies will investigate how ST6Gal I
deficiency affects other lymphoid cells, and how this loss contributes to the
defective anti-viral response.
Recent reports have demonstrated that loss of expression of ST6Gal I by B cells
results in preferential co-localization of the BCR with CD22, a negative regulator
of BCR signaling, in clathrin-rich membrane microdomains (Collins et al., 2006;
Grewal et al., 2006). Aged CD22 deficient mice have been reported to develop
IgM autoantibodies (Walker and Smith, 2008). Ablation of CD22 expression in
ST6Gal I-/- mice rescues BCR signaling defects (Collins et al., 2006). In naïve B
cells, modification of CD22 by ST6Gal I normally results in segregation of CD22
molecules, due to homotypic interactions with the α2, 6 sialic acid cis-ligands of
other CD22 molecules (Collins et al., 2006). Following antigen receptor
engagement, CD22 is tyrosine phosphorylated, and phosphorylated CD22
recruits SHP-1 (Src homology domain2-containing tyrosine phosphatase),
mediating signal inhibition via the BCR (Horikawa et al., 2007; Walker and Smith,
2008). Due to the absence of these cis-CD22 ligands in ST6Gal I-/- mice, there is
increased association of sIgM with the inhibitory receptor CD22 on naïve B cells;
following antigen receptor engagement in vivo, this could result in immediate
attenuated BCR signaling. We speculate that a possible in vivo outcome of this
could be significantly impaired differentiation of naïve B cells into extra-follicular
short-lived plasma cells following viral infection of ST6Gal I-/- mice (Benson et al.,
2007; Fujimoto and Sato, 2007; Junt et al., 2007; Paus et al., 2006; Walker and
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Smith, 2008). Viral-specific B cells in the ST6Gal I-/- mice, with “weak or
moderate BCR” signaling could enter germinal centers and undergo affinity
maturation and differentiation into plasma cells. This could explain why we
observe that after day 14 p.i, influenza-specific IgG responses are quite
comparable to wild-type mice. Thus in a normal immune response, ST6Gal I
modification of glycoproteins on naïve B cells may influence the signaling
threshold required following antigen receptor signaling, and the biological
outcome in vivo would favor differentiation of a greater proportion of Ag-specific
B cells into extra-follicular short-lived plasma cells, important in the early control
of pathogens. Alternatively, the repertoire of B cells available in ST6Gal I-/- mice
could be different from wild-type mice due to differences in signaling strength
during development (Ghosh et al., 2006; Santos et al., 2008).
In conclusion, our data demonstrate that despite early defects in the generation
of an antiviral humoral response, ST6Gal I-/- mice are able to clear virus and
generate potent humoral memory. Further, our data suggests that loss of ST6Gal
I expression by B cells may be responsible for the impaired antiviral IgM
response. Finally, loss of expression of ST6Gal I in non-B cells likely contributes
to the impaired IgG humoral response. Future experiments will elucidate how the
expression of this enzyme by different lymphocyte populations, influences the
generation of an antiviral immune response.
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Figure 2.1. Binding of SNA on B cell populations.
Splenocytes from uninfected C57BL/6 mice, or mice infected with 2x105 pfu
LCMV Armstrong i.p. either 8 or 15 days earlier were used for the analysis. The
left panel in B-D shows the gating, and the right panel SNA binding as
histograms of the gated population. A, Cartoon depicting the glycosyltransferase
ST6Gal I which catalyzes addition of terminal α2,6 sialic acids to galactose. SNA
lectin binds Sia α 2-6Galβ1-4GlcNac. B, Naive B cells from uninfected mice
gated on B220+/IgD+ cells C, CD138+/B220lo plasma blasts on day 8 and D,
B220+FAS+/IgD- germinal center cells all show high SNA binding.
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Figure 2.2. Influenza-specific B cell responses in ST6Gal I-/- mice during
acute infection.
B6 or ST6Gal I-/- mice were infected with influenza A/HKx31 i.n. and bled on
indicated days. A, Serum virus-specific IgM (left), IgG (right) and B, IgG isotypes
on day 7 were measured by ELISA. Data is expressed as the reciprocal endpoint
antibody titer on serial titration of influenza antibody. C, Cell suspensions of CLN,
MedLN and spleen were prepared from individual mice on day 7 p.i., and the
ELISPOT

assay was used to measure the number of cells producing virus-

specific IgM, IgG1, IgG2b, IgG2c, IgG3 or IgA as indicated, with N =6-8 mice per
group. Results are expressed as the number of ASC/105 nucleated cells. (∗,
indicate p < 0.05, ∗∗ indicate p < 0.01, ∗∗∗ indicate p < 0.001)
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Figure 2.3. Germinal center B cells of ST6Gal I-/- mice do not bind GL7.
Mice were infected with influenza x31 i.n. and on day 7 p.i. lymph nodes were
isolated and either frozen for immunofluorescence, or stained for FACS analysis
using germinal center or plasma cell markers. Numbers show percentages of
gated population. A, Immunofluorescence staining of MedLN using B220 and
GL7 or B220 and PNA as indicated. B220 in red and GL7 or PNA staining in
green. B, FACS analysis of germinal center B cells in CLN of same mice, gating
on IgDloB220+ cells. Histogram shows GL7 binding on gated IgDloB220+ cells.
Dot plot shows PNAhighFas+ cell population of gated IgDlowB220+ cells. C, FACS
analysis of plasma cells in CLN gating on CD138+B220+ cells. Histogram overlay
of SNA binding of gated population. Filled histogram shows ST6Gal I-/-, and open
histogram shows B6. Bar graph shows frequencies of total plasma cells in
indicated mice. D, Total number of germinal center B cells in CLN gating on
IgDlowB220+ PNAhighFas+ or IgDlowB220+ GL7+ cells. Bar graphs show data from
n=5 mice. (∗, p < 0.05 and ∗∗, p < 0.01.)
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Figure 2.4. Influenza viral infection and clearance in lungs.
B6 and ST6Gal I-/- mice were infected i.n. and on indicated days post infection,
lungs were collected and assayed for influenza viral titer. Black/filled symbols are
B6 mice and white/open symbols are ST6Gal I-/- mice. Each symbol represents
one mouse tested. The limit of detection is shown by the dotted line.
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Figure 2.5. Influenza-specific T cell responses.
At day 10 p.i., lymphocytes from MedLN and lung were stimulated with indicated
peptides for 5 hrs, and stained for intracellular cytokine production of IFNγ. A,
Representative staining for each tissue gating on CD4 or CD8 T cells. Numbers
indicate the percentage of CD4 or CD8 T cells specific for each peptide. B, Total
NP311-325 specific CD4 or NP366-374 CD8 T cells were enumerated in MedLN
and lung at day 10, n = 4 mice in each group.
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Figure 2.6. Immune influenza-specific IgG responses.
A, Influenza specific IgG isotypes from day 180 sera samples of B6 or ST6Gal I-/mice. B, ELISPOT assay was used to determine the virus-specific IgG1, IgG2b,
IgG2c and IgG3 antibody secreting cells in bone marrow of mice (LLPCs). C,
Memory B cell numbers from spleen and MedLN; cells are pooled from 4 mice for
MedLN, n = 4-8 mice per group.
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Figure 2.7. Loss of expression of ST6Gal I by B cells results in defective
influenza specific IgM.
A, Cartoon depicting experimental protocol where µMT-/- recipient mice were
primed with 107.4 EID50 i.p; 90 days later, 2x107 purified naïve B220+ B cells from
B6 or ST6Gal I-/- mice were adoptively transferred i.v. into mice. Control mice
received no transferred cells. Mice were infected with 106.8 EID50 influenza
A/HKx31 i.n. one day later and bled on indicated days. B, Serum virus-specific
antibodies for IgM or C, IgG levels were detected by ELISA, n = 3 mice in each
group.
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CHAPTER III
ST6GAL I DEFICIENCY RESULTS IN ALTERED SIALYLATION OF
IGG AND IGA, AND PROMOTES IGA MESENGIAL DEPOSITION
FOLLOWING INFLUENZA INFECTION
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Abstract
ST6Gal I, a glycosyltransferase highly expressed by B cells, catalyzes the
addition of α-2, 6 sialic acid to galactose (Siaα2-6Gal), a modification found on
N-linked glycoproteins. Aberrant glycosylation has been associated with the
pathogenesis of IgA nephropathy (IgAN), a disease characterized by immune
complex deposits in the glomerular mesangium, which can lead to end-stage
renal failure in 20-40% of diagnosed patients. We have previously shown that
ST6Gal I-/- mice infected with influenza A/HKx31 demonstrated profound
impairment in the generation of viral-specific humoral responses, although
memory viral-specific IgG levels were normal.
We have further analyzed influenza-specific humoral responses in ST6Gal I-/mice. Here we report the paradoxical finding that at memory, influenza infected
ST6Gal I-/- mice show higher influenza-specific IgA, as well as total IgA,
compared to WT mice, despite impaired early responses. Using MALDI-TOF MS
analysis and immuno-histology, we demonstrate that immune ST6Gal I-/- mice
show significant deficiencies in N-glycan sialylation of IgG and IgA, as well as
increased immunoglobulin deposition in the kidney glomeruli.
These data show that loss of expression of an α-2,6 sialyltransferase, together
with influenza viral infection, results in both aberrant glycosylation of IgG and IgA,
and leads to increased immunoglobulin deposition in kidney glomeruli. These
data raise the possibility that a common form of glomerulonephritis, IgAN, may
be similarly initiated by altered sialyltransferase gene expression in concert with
influenza infection.
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Introduction
The enzyme ST6Gal I is a glycosyltransferase highly expressed by B and T cells
that synthesizes the glycan sequence α2,6 sialic acid linked to galactose (Siaα26Gal) (Hennet et al., 1998). This structure is typically found on N-linked glycans
on glycoproteins such as the mammalian lectin CD22, a transmembrane
glycoprotein expressed by B cells with high specificity for (Siaα2-6Gal). CD22 is
a negative regulator of B cell signaling that recruits SHP-1 to the BCR, thus
attenuating signals via the BCR (Collins et al., 2006; Hennet et al., 1998;
Nitschke, 2005). Several studies of ST6Gal I null mice demonstrated that these
mice show profound impairment in the generation of humoral responses to viral,
protein, and hapten antigens (Hennet et al., 1998; Zeng et al., 2009). These
defective humoral responses observed in ST6Gal I-/- mice are at least partially B
cell intrinsic, and are likely due to impaired B cell responses due to altered colocalization of the BCR with the negative regulator CD22 (Collins et al., 2006;
Grewal et al., 2006; Zeng et al., 2009). Despite defects in the early generation of
humoral responses, ST6Gal I-/- mice control influenza viral infection and generate
potent humoral memory (Zeng et al., 2009).
Humoral immunity is characterized by prolonged antibody production, even after
resolution of infection, in stark contrast to the T cell response, where effector T
cell function is relatively short-lived. Antibodies, by neutralizing or opsonizing free
extracellular pathogens, serve as a critical first-line defense against re-infection.
Humoral immunity is provided by pre-existing antibody produced by a population
of antibody secreting cells (ASCs) termed long-lived plasma cells (LLPCs), as
well as a population of memory B cells (MBCs) that can rapidly differentiate
following antigenic stimulation into plasma cells (Kalia et al., 2006; Slifka and
Ahmed, 1996; Slifka and Ahmed, 1998; Slifka et al., 1998).
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Recently, work from several groups has demonstrated an important role for IgG
terminal glycosylation. Terminal glycans influence binding to Fc receptors and
C1q of complement, and sialylation has specifically been shown to have
important effects on antibody function (Nimmerjahn and Ravetch, 2007; Raju,
2008). Therapeutically, intravenous immune globulin (IVIG), which is used for the
treatment of diverse autoimmune and systemic inflammatory diseases, has been
shown in animal models to mediate enhanced anti-inflammatory effects when
enriched for sialic acid containing IgG (Anthony et al., 2008; Kaneko et al., 2006;
Kaveri et al., 2008). Thus alterations in sialylation of IgG may critically influence
its function and clearance.
In addition to a role for glycosylation in IgG function and human disease, aberrant
glycosylation of IgA has also been implicated in human disease, specifically in
the pathogenesis of IgA nephropathy (IgAN), one of the most common forms of
glomerulonephritis globally (Allen and Feehally, 2000; Nishie et al., 2007; Raska
et al., 2007; Suzuki et al., 2008; Tomana et al., 1999; Xu et al., 2005). Recent
examination of IgAN patients suggested that expression of an α2,6
sialyltransferase (ST6GALNAcII) is significantly reduced in peripheral B cells
from patients suffering from IgAN, and IgAN patients show reduced IgA1 α2,6
sialic acid content (Khan et al., 2008). IgA1 is the dominant circulating subclass
of IgA in humans and primates, but not other species, and is characterized by a
hinge region containing as many as 5 O-linked glycans (Glassock, 2009; Novak
et al., 2008). Although murine IgA does not have the O-glycans characteristic of
human IgA1, a recent study of mice lacking the β-1,4 galactosyltransferase I
(β4GalT-I) reported the spontaneous development of a human IgAN-like disease,
characterized by glomerular lesions, increased IgA levels, and IgA deposition in
kidneys (Nishie et al., 2007). However, only a single infant patient has ever been
diagnosed with a congenital mutation in β4GalT-I, so the relevance of this
enzyme to IgAN disease development in humans remains obscure (Hansske et
al., 2002). Recently, a study found an association between mutations in core 1
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β1,3-galactosyltransferase I (C1β3GalTI) and genetic susceptibility to IgAN,
suggesting that galactose-deficiency may play a role in disease development (Li
et al., 2007a; Novak et al., 2008). This work fits with data suggesting that many
IgAN patients exhibit under-galactosylation of O-glycans in the IgA1 hinge region,
and that abnormal IgA1 glycosylation is a heritable trait (Gharavi et al., 2008).
However, since many family members with abnormal IgA1 glycoforms remain
asymptomatic, additional factors other than aberrant glycosylation appear to be
required for IgAN disease development and pathogenesis (Gharavi et al., 2008).
In the following report, we investigated the nature of alterations in terminal
glycans in serum immunoglobulins from ST6Gal I-/- mice to determine whether
ST6Gal I-/- mice developed any evidence of glomerulonephritis. We show that
despite impaired generation of influenza-specific humoral responses, ST6Gal I-/mice paradoxically showed higher levels of influenza-specific IgA and total IgA by
day 60 p.i. We also show that although levels of influenza-specific IgG and total
IgG were comparable in immune ST6Gal I-/- and WT mice, IgG N-glycans were
characterized by a complete deficiency of terminal sialylation in ST6Gal I-/- mice.
Moreover, while gross pathology of the mesangial matrix and kidney function
remained normal, influenza immune ST6Gal I-/- mice show significant IgA and
IgG deposition in the glomeruli. Examination of glycosylation differences for IgA
also revealed that ST6Gal I-/- IgA showed aberrant terminal sialylation. Our data
raise the possibility that a combination of influenza infection history, as well as
genetic remodeling of protein glycosylation, such as loss of expression of an α2,6
sialyltransferase, may be key factors in the pathogenesis of a common form of
glomerulonephritis.
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Materials and Methods

Mice and immunizations
ST6Gal I-deficient mice were originally generated by J. Marth (University of
California, San Diego) and obtained from the Consortium for Functional
Glycomics and bred in-house, backcrossed to C57BL/6 x10 generations (Hennet
et al., 1998). C57BL/6 female mice were purchased from The Jackson
Laboratory (Bar Harbor, ME). Mice were maintained under specific pathogen-free
conditions at the University of Tennessee in accordance with university IACUC
guidelines. Anesthetized mice were intra-nasally infected with 106.8 EID50
influenza A/HKx31 in 30 µl of PBS, as previously described (Zeng et al., 2009).

Urinalysis
Urine samples from C57BL/6 or ST6Gal I-/- mice were obtained at day 0
(uninfected) or day 380 post-infection (p.i). Chemstrip 5 OB urinalysis strips
(Roche Diagnostics, Indianapolis, IN) were used to test urine samples for
hematuria and proteinuria. Urine samples were also tested for albumin content
via a double-sandwich ELISA kit using affinity-purified goat anti-mouse albumin
antibody and HRP-conjugated goat anti-mouse albumin antibody, as per the
manufacturer’s instructions (Bethyl Laboratories, Montgomery, TX).

Histological Analysis
Kidneys were harvested from influenza immune mice, fixed in 10% formalin,
embedded in paraffin and thin sections cut on a microtome. Sections were
stained with H&E, PAS, and Masson’s Trichrome.
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Immunohistochemistry
Kidneys were harvested from mice at day 0 and day 400 p.i. and frozen in O.C.T.
compound at -80°C. Kidneys were sectioned at 7 µm, and frozen sections were
blocked with 3% BSA in PBS, stained with IgG-biotin or IgA-biotin, followed by
streptavidin-AlexaFluor 488. Sections were examined using an epi-fluorescent
microscope (Nikon Eclipse E600). The mean fluorescence was measured on the
same samples using a Nikon NIS-Elements BR 2.30, measuring the MFI of three
randomly selected glomeruli per sample. Unpaired student t tests were
performed to determine statistical significance with *denoting p<.05 ** denoting
P<0.01.

Immunoglobulin Measurement by ELISA
Total IgA or total IgG was measured in serum or vaginal washes of individual
mice at day 0, day 7, day 14 or day 60-175 p.i. with influenza. Plates were
coated with goat anti-mouse IgA or goat anti-mouse IgG (Southern Biotech,
Birmingham, AL) and incubated at 4°C overnight. Plates were washed with PBSTween 20 (0.05%), blocked with PBS-BSA (3%), and washed again. Serial 3fold sample dilutions were prepared in PBS-Tween 20 (0.05%) and BSA (0.5%).
The plates were incubated at room temperature for 4 h or overnight at 4°C then
washed thoroughly.

Plate-bound secreted Abs were detected using alkaline

phosphatase-conjugated goat anti-mouse Abs with specificity for IgA or IgG
(Southern Biotech) diluted in PBS-BSA (1%) and incubated for 4 h at room
temperature or overnight at 4°C. Plates were then washed thoroughly, and color
development with p-nitrophenyl phosphate (Sigma-Aldrich, St. Louis, MO) in
diethanolamine buffer was read at 405 nm using a Synergy II Multi-Detection
Microplate Reader (Bio-Tek Instruments, Winooski, VT).

The Ab titer is

expressed as the reciprocal of the highest dilution giving an absorbance value
more than twice that for simultaneously titrated samples from naïve mice.
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Influenza-specific titers were measured as previously described (Sangster et al.,
2003; Zeng et al., 2009).

IgG and IgA purification
IgGs were purified from serum samples on a FPLC system by affinity
chromatography at a flow rate of 1ml/min. Mouse serum (1 ml) was loaded on a 1
ml protein A/G affinity column that had previously been equilibrated with 100 mM
NaPO4, 150 mM NaCl, pH 7.2 (buffer A). The column was subsequently washed
with 10 column volumes of buffer A. Bound IgGs were eluted with 0.1 M glycin
pH 2.3. Fractions of 500 µL were collected in tubes containing 50-µL
neutralization buffer (1M Tris, pH 8.8). Finally, all the fractions containing
antibodies were pooled and concentrated using 30-kDa cut-off filter system. For
IgA, mouse serum (400 µL) was applied to 600µL Jacalin-sepharose slurry
previously equilibrated with buffer A. The mixture was incubated for 30 min at
room temperature then the beads were washed extensively as follows: first 400
µL, then 1500 µL buffer A, each with 15 min. incubation under rotation. IgAs were
eluted from the slurry in 1.5 ml buffer A supplemented with 0.1 M α-D-galactose.

N-glycan release
IgG (50 µg) were digested with trypsin for 16 h at 37°C. The reaction was
terminated by heating the sample for 5 min at 95°C. Antibodies were further
digested with 100 mU PNGase F (EC 3.5.1.52; Roche Applied Science, IN) for
18 h at 37°C. Released N-glycans were isolated and desalted on reverse-phase
Sep-Pak C18 cartridges (Alltech, Deerfield, IL) followed by carbograph extractclean columns (Alltech, Deerfield, IL) (von Horsten et al., 2010).
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Sialidase digestion and Permethylation
IgA samples, dissolved in 50mM phosphate buffer pH 6.0, were digested
overnight at 37°C with 5 U/ml Streptococcus pneumoniae neuraminidase
(sialidase S) (GKX-80020, Prozyme, San Leandro, CA). Permethylation was
carried out using methyl iodide as described previously (von Horsten et al., 2010;
Wedepohl et al., 2010). After the reaction, chloroform was added and the
chloroform phase was washed with water until the pH of the water phase was
neutral. The chloroform phase was finally evaporated under reduced atmosphere
and the sample was dissolved in 75% aqueous acetonitrile for MALDI-TOF
measurements.

Mass spectrometry
MALDI-TOF mass spectra were recorded on a Ultraflex III mass spectrometer
(Bruker Daltonics) equipped with a Smartbeam laser and a LIFT-MS/MS facility.
Spectra were recorded in reflector positive ionization mode. 0.5 µl desialylated or
permethylated N-glycans were mixed on the ground steel target in a ratio 1:1 with
the matrix consisting of D-arabinosazone (5 mg/ml) dissolved in 70% aqueous
ethanol (Wedepohl et al., 2010). Calibration was performed on a glucose ladder.

Results
Increased IgA levels in influenza immune ST6Gal I-/- mice
We have previously examined influenza-specific antibody responses in ST6Gal I/-

mice and showed significant impairment in the generation of influenza-specific

IgM and IgG responses (Zeng et al., 2009). However, memory B cell (MBC) and
long-lived plasma cell (LLPC) responses were robust in immune ST6Gal I-/- mice
(Zeng et al., 2009). In this study, we analyzed influenza-specific IgA responses.
In naïve mice, there were no significant differences in total IgG or total IgA
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comparing WT and ST6Gal I-/- mice (Figure 3.1A). However, we discovered that
levels of total IgA, as well as influenza-specific IgA, were significantly higher in
immune ST6Gal I-/- mice at day 175 (Figure 3.1A). To examine this difference in
more detail, mice were infected with influenza A/HKx31 i.n. and mice were
serially bled to obtain longitudinal samples from individual mice. While both
influenza-specific IgG and influenza-specific IgA were significantly reduced at
day 7 in ST6Gal I-/- mice, by day 15 IgG and IgA levels were similar, and by day
60 (memory), influenza-specific IgA levels had surpassed levels in WT mice, in
contrast to influenza-specific IgG, which remained comparable (Figure 3.1B). We
also observed increased influenza-specific IgA levels in mucosal secretions of
ST6Gal I-/- mice (data not shown).
Since circulating IgA levels were higher in ST6Gal I-deficient mice, we examined
whether these mice exhibited any defects in kidney function since high levels of
serum IgA is a hallmark of IgAN. Urine samples were collected from immune
mice and examined for the presence of blood (hematuria) or proteins
(proteinuria) using urinalysis test strips (Table 3.1). We also measured urine
albumin levels by ELISA (Figure 3.1C). ST6Gal I-/- mice were similar in all
measures of kidney function to WT mice (Figure 3.1C and Table 3.1).
Histological analysis of kidney sections from immune mice by H&E (Figure 3.1D)
or PAS staining (not shown) revealed similarly normal gross pathology, with no
evidence of mesangial proliferation in the glomeruli.

ST6Gal I-/- mice show greater IgG deposition in glomeruli following
influenza infection
The first description of IgAN disease established that immunoglobulin deposition
preceded development of pathological abnormalities in kidney (Berger and
Hinglais, 1968). Since ST6Gal I-/- mice exhibited normal gross pathology of the
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kidneys, we examined kidney glomeruli to determine whether there was evidence
of immunoglobulin deposition. Frozen kidney sections from uninfected (naïve)
WT and ST6Gal I-/- mice were first examined for IgG deposition in the glomeruli
by immuno-fluorescence. No significant deposition was observed in either naïve
WT or naïve ST6Gal I-/- mice (Figure 3.2A, upper panels). However, both WT and
ST6Gal I-/- influenza immune mice showed significant IgG deposition in the
glomeruli compared to naïve mice (Figure 3.2A, lower panels), consistent with
several studies that have previously established that immunization or infection
results in increased immune complex deposition in the kidney that is easily
detected by immuno-fluorescence (Dixon et al., 1961; Semkow and Wilczynski,
1979a; Semkow and Wilczynski, 1979b).

To ascertain if there were any

differences in IgG deposition comparing immune WT versus immune ST6Gal I-/mice, we measured mean fluorescence intensity (MFI) of IgG in the kidney
glomeruli (Figure 3.2B). This additional analysis revealed that ST6Gal I-/- immune
mice showed a consistent trend of greater IgG deposition (~30%) compared to
WT immune mice (p<0.05).

Taken together, these data show that following

influenza infection, WT and ST6Gal I-/- mice show significant IgG deposition in
the kidney glomeruli, however ST6Gal I deficiency leads to higher IgG
deposition.

ST6Gal I expression is required for sialylation of N-glycans on IgG
Since IgG levels were similar in all groups of mice, but IgG deposition varied
(Figure 3.1A, 3.2B), we hypothesized that changes in the quality of IgG were
contributing to differences in IgG deposition in the kidney glomeruli. Following
influenza infection of mice, there is a significant increase in influenza specific-IgG
titers (Figure 3.1B), resulting in the formation of antigen-antibody immune
complexes that deposit in kidneys (Figure 3.2 and (Semkow and Wilczynski,
1979b)). However, it has also been known for many years that significant
changes occur in glycosylation during an immune response, with substantial
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changes in lectin binding such as peanut agglutinin (PNA) binding by B and T cell
glycoproteins and glycolipids (Galvan et al., 1998b; Kersh et al., 2003; London et
al., 1978; Onami et al., 2002; Schrader et al., 1982). Aberrant immunogobulin
glycosylation

has

been

proposed

to

influence

the

pathogenesis

of

glomerulonephritis by influencing clearance mechanisms of immune complexes
from the circulation (Novak et al., 2008).
We examined alterations in IgG N-glycans by performing MALDI-TOF analysis of
purified IgG from sera samples from naïve and immune WT, as well as naïve and
immune ST6Gal I-/- mice. N-glycans were released and isolated from IgG
samples, and they were subsequently permethylated for mass spectrometric
analyses by MALDI-TOF-MS. When we compared N-glycans of IgG for naïve
versus influenza immune WT mice, we observed no significant changes (Figure
3). Similarly, no differences were observed comparing naïve and immune
ST6Gal I-/- IgG (Figure 3.3). These data confirm that overall, composition of IgG
N-glycans remains similar before and after influenza infection. Importantly, our
analysis revealed that sialylated N-glycans of IgG, which were present in WT
mice, were completely absent in ST6Gal I-/- IgG (Figure 3.3, right panels). This
deficiency of sialylated N-glycans was seen with IgG purified from both naïve and
immune ST6Gal I-/- mice (Figure 3.3). In the IgG fraction from WT mice, monoand di-sialylated N-glycans could be found in both naive and influenza immune
samples at m/z 2431.2, 2635.4 and 3026.6. This observation suggests that
Neu5Gc in IgG N-glycans are exclusively (α-2,6)-linked. These results provide
evidence that ST6Gal I expression is required for the synthesis of sialylated Nglycans on mouse IgG.

Loss of ST6Gal I expression leads to aberrant IgA glycosylation
Since our analysis of IgG N-glycans revealed significant changes in sialylation,
we asked whether similar changes occurred in IgA. We therefore performed
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MALDI-TOF analysis of N-glycan structures from purified IgA obtained from
serum samples from WT and ST6Gal I-/- mice to examine changes in N-glycan
sialylation of IgA. Previous reports have established that N-glycans of IgA are
sialylated bi-and tri-antennary complex-type glycans (Lipniunas et al., 1993).
These sialylated N-glycans are acidic and generally give poor MALDI mass
spectra (Harvey, 1999; Nishie et al., 2007). We therefore examined mass spectra
of IgA N-glycans before and after digestion with an α2,3 sialidase.
N-glycans were released and isolated from IgA and were subsequently
permethylated for mass spectrometric analyses by MALDI-TOF-MS. A fraction of
the IgA samples was digested with sialidase S before being permethylated. As
shown in Figure 3.4A, before treatment with sialidase, IgA samples contained
sialylated N-glycans and no differences were noted comparing WT and ST6Gal I/-

IgA. However, following sialidase treatment clear differences were noted

between WT and ST6Gal I-/- IgA (Figure 3.4B). Comparing purified IgA from WT
versus ST6Gal I-/- mice, we discovered that α2,3 sialidase abolished virtually all
sialylated N-glycans in ST6Gal I-/- IgA (Figure 3.4B). In contrast, sialylated Nglycans remained prominently visible on IgA from WT samples treated with α2,3
sialidase (Figure 3.4B). Similar results were obtained using IgA from naïve WT
mice compared to naïve ST6Gal I-/- mice (data not shown). These data
demonstrate that mouse IgA contains both α2,3- and α2,6-linked sialic acids on
N-glycans, in contrast to mouse IgG where loss of expression of ST6Gal I
revealed that sialic acids on N-glycans were exclusively α2,6-linked (Figure 3.3).
Moreover, these data illustrate that loss of expression of ST6Gal I results in
significant alterations in sialylation of N-glycans of IgG and IgA.
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Loss of ST6Gal I expression and influenza infection results in mesangial
IgA deposition
Finally, since our data indicated immune ST6Gal I-/- mice had high circulating
levels of aberrantly glycosylated IgA, we examined kidney glomeruli of WT and
ST6Gal I-/- mice by immuno-fluorescence to determine whether they showed IgA
deposition. Naive WT mice show little evidence of IgA deposition in the glomeruli,
and this was also true for naïve ST6Gal I-/- mice (Figure 3.5A, upper panels).
Immune WT mice also showed little evidence of IgA deposition. In contrast,
immune ST6Gal I-/- mice showed significant mesangial IgA deposition (Figure
3.5A, lower panels). Measurement of IgA mean fluorescence confirmed our
observation of significantly higher deposition (Figure 3.5B). In contrast to IgG
deposition, where we observed that influenza infection of both WT and ST6Gal I-/mice resulted in IgG deposits in the kidney glomeruli, IgA deposition was only
evident in immune ST6Gal I-/- mice (Figure 3.2 and 3.5). Thus, IgA deposition
appeared to be influenced both by 1) immune history and 2) genetic remodeling
of protein glycosylation. Perhaps, altered sialylation of N-glycans causes a
conversion to occur, transforming normal IgA into pathogenic IgA, resulting in IgA
mesangial deposition in ST6Gal I-/- influenza immune mice.

Discussion
Glycosylation is an important post-translational modification that influences
several aspects of protein function, including conformation, stability, activation,
and clearance from the circulation. Aberrant glycosylation has been implicated in
several human diseases including cancer and metastasis, leukocyte adhesion
deficiency diseases (LAD/CDG-IIc), and muscular dystrophy (Freeze and
Schachter, 2009; Varki., 2009). Understanding how changes in glycosylation
contribute to disease pathogenesis may provide clues for advances in clinical
treatment.
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We have previously reported that mice deficient in ST6Gal I-/- show altered
immune responses, including significant impairments in the generation of
humoral responses (Hennet et al., 1998; Zeng et al., 2009). In this report, we
make the paradoxical observation that although generation of influenza-specific
IgA responses are also impaired in ST6Gal I-/- mice, by memory time-points
immune ST6Gal I-/- mice display increased levels of circulating viral-specific and
total IgA (Figure 3.1). Our observation of increased IgA levels in immune ST6Gal
I-/- mice led us to examine whether these mice developed evidence of
glomerulonephritis.
Analysis of immune ST6Gal I-/- mice revealed that although these mice show
evidence of normal kidney function (Figure 3.1 and Table 3.1), they also show
increased IgG and IgA deposition in kidney glomeruli (Figure 3.2 and Figure 3.5).
Glycan analysis of IgG and IgA by MALDI-TOF revealed that N-glycans of both
IgG and IgA from ST6Gal I-/- mice show aberrant glycosylation (Figure 3.3 and
Figure 3.4). These alterations in glycosylation were characterized by significant
losses in sialylation as evidenced by a complete deficiency of terminally
sialylated N-glycan structures in IgG, and reductions in sialylated N-glycans in
IgA (Figure 3.3 and 3.4). Together, these data suggest that expression of this
α2,6 sialyltransferase is critical for the synthesis of terminal sialic acids on IgG
and IgA, and may influence circulating antibody levels and immunoglobulin
deposition in the kidney glomeruli.
The sialic acid content of antibodies has been proposed to play a key role in the
anti-inflammatory therapeutic effect of IVIG via Fc interactions with activating and
inhibitory FcγRs (Nimmerjahn and Ravetch, 2007). Although it plays a primary
role in protective humoral immunity, IgG also plays a pathogenic role in
autoimmune diseases via the generation of auto-antibodies such as occurs in
systemic

lupus

erythematosus

(SLE),

immune

thrombocytopenia

(ITP),

rheumatoid arthritis (RA), and multiple sclerosis (MS). Pooled polyclonal IgG
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from the sera of thousands of donors is used to make IVIG that is in turn used
both for replacement therapy for patients lacking immunoglobulins, and in high
doses as an anti-inflammatory agent for the treatment of autoimmune diseases
such as ITP, SLE, MS, and scleroderma (Nimmerjahn and Ravetch, 2007).
Several models have been proposed to account for the anti-inflammatory activity
of Fc fragments in IVIG, and one model proposes that sialic acid rich IgG
facilitates the induction of inhibitory FcγRIIB on effector macrophages, increasing
the threshold for cell activation, thus reducing inflammation (Nimmerjahn and
Ravetch, 2007). Enrichment of sialic acid containing IgG significantly lowers the
amount of IVIG needed for its anti-inflammatory activity (Kaneko et al., 2006).
The deficiency of sialylated N-glycans on IgG from ST6Gal I deficient mice would
presumably alter this proposed interaction of Fc-bearing sialic acids with sialic
acid binding receptors on regulatory macrophages. This in turn may lead to
reduced ability for IgG derived from ST6Gal I-/- mice to upregulate FcγRIIB on
effector macrophages.
In addition to changes in the sialylation of IgG, our data also revealed significant
alterations in the sialylation of IgA (Figure 3.4). In humans, abnormalities in
galactosylation and sialylation of IgA1 have been reported to play a key role in
pathogenesis of IgAN. IgA1, which is not produced in mice, is modified by
ST6GalNAcII, an α2,6 sialyltransferase that modifies O-glycans of the IgA1 hinge
region (Li et al., 2007b). Reduced expression of ST6GalNAcII has previously
been reported in peripheral B cells from IgAN patients (Khan et al., 2008).
However, another report using immortalized B cell lines from IgAN patients
reached a different conclusion suggesting that ST6GalNAcII was increased in
expression, while two other glycosyltransferases (C1GalT1 and Cosmc) were
reduced in expression (Suzuki et al., 2008). The discrepancies in the conclusions
of the two studies may be due to the different patient groups, and/or differences
in the cells used in the two studies (peripheral B cells versus immortalized B
cells) to examine ST6GalNAcII expression. However, it should also be
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considered that transcriptional regulation of α2,6 sialyltransferases is known to
be influenced by cell type, differentiation, and transformation status (Hedlund et
al., 2008; Li et al., 2007b).
Our results using influenza infection of mice deficient in ST6Gal I, the α2,6
sialyltransferase involved in N-glycan sialylation, demonstrated not only aberrant
terminal sialylation of N-glycans from ST6Gal I-/- IgA, but also increased
circulating IgA, and increased IgA deposition in kidney glomeruli. These
observations would be consistent with early development of an IgAN-like disease
in ST6Gal I-/- mice. Our findings are reminiscent of the initial study by Berger and
Hinglais characterizing IgAN (aka Berger’s disease) where they first proposed
using immuno-fluorescence techniques to diagnose this disease (Berger and
Hinglais, 1968). In their study, increased glomerular IgA deposition preceded
disease development, as well as evidence of pathological abnormalities in the
kidney (Berger and Hinglais, 1968). A recent study proposed that carbohydrates
of serum IgA may be involved in the development of IgAN-like diseases,
regardless of whether they are O-or N-glycans, and our data would support this
conclusion, although the mechanism of pathogenesis remains unclear (Nishie et
al., 2007). Importantly, while changes in terminal N-glycan sialylation were
evident in IgG and IgA before influenza infection of ST6Gal I-/- mice, no
significant differences in immunoglobulin deposition were observed in nonimmunized mice compared to WT mice. Our observations of increased
deposition were limited to mice with a history of influenza infection. We observed
no evidence of spontaneous IgAN-like disease development as reported in the
study of β4GalT I-/- mice (Nishie et al., 2007).
Interestingly, our data is consistent with several familial studies of IgAN that have
suggested that additional co-factors besides altered glycosylation may be
required for IgAN disease development, such as respiratory infections (Gharavi
et al., 2008; Woodroffe et al., 1980). One clinical study showed that patients with
80

IgAN are high responders for IgA production following administration of influenza
vaccine (Endoh et al., 1984). We also observed higher memory influenza-specific
IgA responses in ST6Gal I-/- mice compared to WT mice (Figure 3.1). However, it
remains unclear what mechanisms mediate the increased flu-specific IgA levels
in ST6Gal I-/- mice. One possibility is that more IgA-specific plasmablasts are
generated in ST6Gal I-/- mice, and this accounts for the increased circulating
levels of IgA. However, our data analyzing the generation of influenza-specific
IgA plasmablasts showed modest defects in ST6Gal I-/- mice, and influenzaspecific IgA LLPC and MBC numbers were similar comparing WT and ST6Gal I-/immune mice ((Zeng et al., 2009) and data not shown). If so, this would suggest
that higher IgA levels in influenza immune ST6Gal I-/- mice was more likely due to
defective IgA clearance, or higher per cell production of IgA. While further studies
are needed to examine this in more detail, we favor the former explanation since
it has been proposed that immune complexes of aberrantly glycosylated IgA1
escape normal clearance mechanisms, and deposit in the renal mesangium
where they induce glomerular injury in humans (Novak et al., 2008). A similar
phenomenon may occur with aberrantly glycosylated IgA in ST6Gal I deficient
mice. Possibly, these mice may provide a useful model by which influenza
infection, and the generation of under-sialylated IgA (and IgG), can be evaluated
to determine how genetic remodeling of protein glycosylation and immune history
together

contribute

to

immunoglobulin

deposition

and

development

of

glomerulonephritis.
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Figure 3. 1. Increased IgA levels in influenza immune ST6Gal I-/- mice.
C57BL/6 wildtype or ST6Gal I-/- mice remained uninfected or were infected with
106.8 EID50 of influenza A/HKx31 i.n. and serum, urine, or kidney samples were
collected. ELISA was performed on samples to measure total or influenzaspecific Ig, or albumin levels. (A) Serum levels were measured of total IgG and
IgA from naïve, uninfected mice (left), or total IgG, total IgA, and influenzaspecific IgG and IgA from mice at day 175 post-infection (right). (B) Mice were
serially bled on indicated days and virus-specific IgG and IgA were measured
longitudinally. (C) Albumin levels were measured in urine from mice at day 400
post-infection. (D) Kidneys from mice at day 400 post-infection were formalin
fixed, paraffin-embedded, and thin sections were stained with H&E. Magnification
600X. Bar graphs show data from n = 4-10 mice, with black bars showing WT
mice and white bars showing ST6Gal I-/- mice (* indicates p<0.05 and ** indicates
p<0.01)
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Table 3. 1 Measurement of hematuria and proteinuria by urinalysis test
strips.
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Figure 3. 2. ST6Gal I-/- mice show greater IgG deposition in glomeruli
following influenza infection.
WT or ST6Gal I-/- mice remained uninfected or were infected with 106.8 EID50 of
influenza A/HKx31 i.n. and on day 400 kidneys were harvested and frozen for
immuno-histology. (A) Representative staining of IgG in kidney glomeruli from
naïve WT or ST6Gal I-/- mice (top) compared to WT or ST6Gal I-/- at day 400
post-infection (bottom). (B) Mean fluorescence intensity of IgG deposition was
measured in influenza immune mice. Bar graphs show data from n = 6 samples
from two independent experiments, with black bars denoting WT and white bars
denoting ST6Gal I-/- mice (* indicates p<0.05).
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Figure 3. 3. ST6Gal I expression is required for sialylation of N-glycans on
IgG.
MALDI-TOF spectra of permethylated N-glycan pools were measured in the
positive-ion mode. All molecular ions are present in sodiated form [M + Na]+. (A)
IgG from naive mice, or (B) IgG from mice on day 100 post-infection with
influenza comparing WT (left) or ST6Gal I-/- (right). Green circle, Man; yellow
circle, Gal; yellow square, GalNAc; blue square, GlcNAc; red triangle, Fuc; white
diamond, Neu5Gc. Structures outside the bracket have not been unequivocally
assigned.
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Figure 3. 4. Loss of ST6Gal I expression leads to aberrant IgA
glycosylation.
MALDI-TOF spectra of permethylated N-glycan pools were measured in the
positive-ion mode. All molecular ions are present in sodiated form [M + Na]+. (A)
IgA and (B) IgA digested with sialidase S prior to permethylation from influenza
immune WT (left) or ST6Gal I-/- (right) mice. Green circle, Man; yellow circle, Gal;
yellow square, GalNAc; blue square, GlcNAc; red triangle, Fuc; white diamond,
Neu5Gc. Structures outside the bracket have not been unequivocally assigned.
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Figure 3. 5. Loss of ST6Gal I expression, concomitant with influenza viral
infection, result in mesangial IgA deposition.
WT or ST6Gal I-/- mice remained uninfected or were infected with 106.8 EID50 of
influenza A/HKx31 i.n. and on day 400 kidneys were harvested and frozen for
immuno-histology. (A) Representative staining of IgA in kidney glomeruli from
naïve WT or ST6Gal I-/- mice (top) compared to WT or ST6Gal I-/- at day 400
post-infection (bottom). (B) Mean fluorescence intensity of IgA deposition was
measured in influenza immune mice. Bar graphs show data from n = 6 samples
from two independent experiments, with black bars denoting WT and white bars
denoting

ST6Gal

I-/-

mice

(**

indicates

p<0.01).CHAPTER

II

ST6Gal I promotes rapid IL-2Rα surface expression, increasing early proliferation
of terminal effector CD8 T cell.
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CHAPTER IV
ST6GAL I PROMOTES RAPID IL-2Rα SURFACE EXPRESSION,
INCREASING EARLY PROLIFERATION OF TERMINAL
EFFECTOR CD8 T CELLS
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Abstract
ST6Gal I is a glycosyltransferase highly expressed by lymphocytes and cancer
cells that catalyzes the addition of α2,6 sialic acid to galactose (Siaα2-6Gal) on
N-linked glycoproteins. We discovered that ST6Gal I shows dramatic changes in
gene expression during memory CD8 T cell differentiation that corresponds with
lectin binding, but the significance of this regulated carbohydrate modification
remained elusive. To identify the role of these regulated glyco-phenotypic
changes, we infected ST6Gal I-/- mice and show that viral-specific T and B cell
expansion was impaired. Moreover, defective viral-specific CD8 T cell expansion
was due to early intrinsic defects in proliferation of terminal effector cells,
whereas memory precursor development was enhanced. We provide direct
evidence that loss of ST6Gal I expression by CD8 T cells resulted in delayed
surface expression of IL-2Rα in vivo due to impaired IL-2/IL-2R signaling. These
results suggest that CD8 T cells regulate ST6Gal I expression to promote
proliferation induced by cytokine-dependent signaling.
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Introduction
Over the past several decades it has been appreciated that lymphocytes show
dramatic changes in lectin binding during development and differentiation
(Galvan et al., 1998b; Harrington et al., 2000; London et al., 1978; London and
Horton, 1980; Onami et al., 2002; Rose et al., 1980; Rose et al., 1981). Changes
in lectin binding properties were exploited before the wide availability of
monoclonal antibodies, allowing for the routine purification of cell subsets. For
example, peanut agglutinin (PNA) which recognizes (Galβ1-3GalNAc) on Olinked glycans was used to distinguish developing CD4+CD8+ thymocytes from
SP mature T cells, as well as germinal center B cells from naïve, resting B cells
(London et al., 1978; London and Horton, 1980; Rose et al., 1980). More
recently, effector and memory T cell populations were shown to bind PNA highly,
while naïve T cells showed much weaker binding by this lectin (Galvan et al.,
1998b; Onami et al., 2002). Additionally, naïve, effector, and memory T cell
populations show changes in CD43 glycoform expression which can be
visualized by changes in binding with the glycosylation-dependent monoclonal
antibody, 1B11 (Harrington et al., 2000; Onami et al., 2002). Although little is
known about the significance of altered glycosylation in T cell activation and
function, several studies have demonstrated that changes in the gene expression
of specific glycosyltransferases are responsible for glyco-phenotypic changes
observed in T cell populations (Comelli et al., 2006; Priatel et al., 2000). These
studies suggest that precise regulation of enzyme expression occurs during T
cell development, activation, and differentiation, and is often responsible for
observed glyco-phenotypic changes. However, the functional significance of
these glyco-phenotypic changes has remained poorly understood.
Alterations in glycosylation have been defined in several immune-mediated
diseases, immuno-deficiencies, and cancer. Among the best-studied examples
include the recruitment of leukocyte populations to lymphoid organs and sites of
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infection, which is critically dependent on fucosylated, sialylated glyco-conjugates
such as the sialyl Lewis X (sLex) structure (Harp and Onami, 2010; Lowe, 2003).
A leukocyte adhesion deficiency disease, LADII (also known as congenital
disorder of glycosylation IIc of CDG-IIc) is caused by mutations in a GDP-fucose
transporter (SLC35C1), resulting in hypo-fucosylation of glycoproteins, and
consequent impairment in leukocyte interaction with vascular endothelium (Luhn
et al., 2001). In cancer, one of the hallmark features of malignant cells is altered
sialylation, and specific glycan structures are commonly used as markers of
tumor progression (Varki, 2008). ST6Gal I, a glycosyltransferase that catalyzes
the addition of α2,6 sialic acid to galactose (Siaα2-6Gal) on N-linked
glycoproteins, is up-regulated by oncogenic ras, and shows high expression in
several tumors including cervical, colorectal, breast, and hepatocellular tumors
(Dall'Olio et al., 2004; Hedlund et al., 2008; Vazquez-Martin et al., 2005; Wang et
al., 2002). Several studies have suggested that ST6Gal I expression regulates
tumor cell differentiation, motility, and migration (Christie et al., 2008; Hedlund et
al., 2008; Qian et al., 2009; Seales et al., 2005).
To gain insight into the glyco-phenotypic changes that occur following T cell
activation

in

vivo,

we

undertook

a

comprehensive

examination

of

glycosyltransferase gene expression during memory CD8 T cell differentiation
using the NIGMS Consortium for Glycomics Glyco-gene chip. We identified
changes in glyco-specific gene expression, including changes in the expression
of the sialyltransferase ST6Gal I, which showed a striking decrease during the
naïve to effector cell transition. In contrast to the results observed in T cells, B
cells do not show dramatic reduction in ST6Gal I expression following B cell
activation (Comelli et al., 2006; Zeng et al., 2009). We confirmed that changes in
ST6Gal I expression in CD8 T cells were accompanied by concomitant changes
in cell surface glycosylation, using the lectin Sambucus nigra agglutinin (SNA)
that recognizes the Siaα2-6Gal linkage created by ST6Gal I on N-linked glycans.
Surprisingly, SNA defined heterogeneity in memory CD8 T cells, with SNAhigh
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and SNAlow memory CD8 T cell populations present in all tissues following viral
resolution. Extensive comparison of SNAhigh and SNAlow memory CD8 T cells
with regard to other markers of effector or memory T cells failed to identify any
other marker that uniquely distinguished these populations. However, these two
populations differed with respect to extent of proliferation and kinetics of viral
clearance, suggesting functional heterogeneity within the memory CD8 T cell
compartment.
To further investigate the importance of ST6Gal I regulation during memory CD8
T cell differentiation, we undertook a detailed analysis of LCMV-specific
responses in ST6Gal I deficient mice. These studies identified early impairments
in viral-specific T and B cell responses. Strikingly, we observed that expansion of
short-lived effector cell (SLEC) or terminal effector populations were significantly
impaired, while ST6Gal I-/- T cells preferentially developed into memory precursor
effector (MPEC) populations. We generated transgenic P14xST6Gal I-/- mice, to
obtain CD8 T cells specific for the GP33-41 peptide of the LCMV glycoprotein, to
probe cell intrinsic defects. We discovered that CD8 T cell loss of ST6Gal I
expression resulted in defective early proliferation, and this defective proliferation
was not due to defective T cell recruitment, but rather altered kinetics of IL-2Rα
up-regulation and surface expression in the initial 24hrs following antigen
exposure. We further show that this was due to impaired IL-2/IL-2Rα signaling.
Our

results

provide

the

first

direct

evidence

that

regulation

of

a

glycosyltransferase responsible for post-translational carbohydrate modification
of several T cell glycoproteins, influences early T cell proliferation by fine-tuning
cytokine dependent signaling, and this in turn influenced effector/memory T cell
programming.
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Materials and Methods

Mice and immunizations
All animals were handled in strict accordance with good animal practice as
defined by the University of Tennessee IACUC committee, and the committee
approved all animal work. ST6Gal I-deficient mice were originally generated by J.
Marth (University of California, San Diego) and obtained from the Consortium for
Functional Glycomics and bred in-house, backcrossed to C57BL/6 x10
generations (Hennet et al., 1998). Transgenic P14 Thy1.1 mice were kindly
provided by Dr. Rafi Ahmed (Emory Vaccine Center, GA) and bred in-house.
C57BL/6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME).
Mice were maintained under specific pathogen-free conditions at the University
of Tennessee in accordance with university IACUC guidelines. Mice were
infected with 2×105 PFU LCMV-Armstrong intra-peritoneal (i.p.) or intravenous
(i.v.) as indicated. For memory re-challenge experiments, mice were rechallenged i.v. with 5×107 PFU Vaccinia virus expressing GP33-41 (Onami et al.,
2002).

Adoptive transfer
All antibodies were purchased from BD-Pharmingen (La Jolla, CA). SNA-FITC
was purchased from Sigma Chemicals (St. Louis, MO). DbGP33-41 MHC
tetramers were prepared as previously described (Murali-Krishna et al., 1998) or
provided by the NIH Tetramer Facility (Atlanta, GA). P14xThy1.1 chimeric mice
were generated as previously described (Suvas et al., 2007). Briefly, 0.5-1x106
total Thy1.1 P14 transgenic spleen cells were adoptively transferred into intact
C57BL/6 mice followed by infection with 2x105 PFU of LCMV-Armstrong i.p.
For single transfer experiments, ST6Gal-I+/- x P14 Tg+ Thy 1.1-1.2+ (Tg WT) and
ST6Gal-I-/- x P14 Tg+ Thy 1.1-1.2+ (Tg KO) mice were sacrificed, spleens were
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collected, and processed to yield a single cell suspension. 1x106 Tg WT or Tg
KO cells in 0.5 ml PBS were injected into naïve C57BL/6 Thy1.2+ recipient mice
by tail vein (i.v.) injection. Recipient mice were infected with 2x105 pfu/ml LCMV
Armstrong i.p. or i.v. the next day. Mice were sacrificed at day 8 post- infection
and spleens were collected, processed, and single cell suspensions were stained
with fluorochrome conjugated anti-Thy1.1, anti-Thy1.2, anti-CD8 antibodies,
SNA, and DbGP33-41 MHC-I tetramer for analysis by flow cytometry. All samples
were run on a FACSCalibur (BD Biosciences) and analyzed using FlowJo
software (Tree Star). Total number of donor cells in recipient mice was calculated
from the percent of Thy1.1-1.2+DbGP33-41+CD8+ cells in total splenocytes.
Unpaired t tests were performed to determine statistical significance, with ***
denoting p<0.001, ** denoting p<0.01, and * denoting p<0.05.
For competition co-transfers, ST6Gal I+/- x P14 Tg+ Thy 1.2+ (Tg WT) and ST6Gal
I-/- x P14 Tg+ Thy 1.1-1.2+ (Tg KO) mice were sacrificed, spleens were collected,
and processed to yield a single cell suspension. A 1:1 mixture of Tg WT and Tg
KO cells in a total of 1x106 cells in 0.5 ml PBS per mouse were transferred into
recipient C57BL/6 Thy1.1+ mice i.v. Recipient mice were infected with 2x105
pfu/ml LCMV Armstrong i.p. 24 hours following adoptive transfer. Mice were
sacrificed at day 8 post-infection, spleens were collected, processed, and single
cell suspensions were stained and analyzed as above.
For memory functional experiments, SNAhigh, SNAlow, or total Thy1.1+ CD8+ T
cells were FACS sorted using a FACS Advantage (BD La Jolla, CA) from
immune (day 100) P14xThy1.1 chimeric mice, and 2x104 sorted memory T cells
were adoptively transferred into C57BL/6 mice, followed by challenge with 2x106
LCMV clone 13 i.v. Mice were serially bled and serum and PBMC were analyzed
from individual mice as indicated.
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DNA Microarray Hybridization
Total RNA was isolated from FACS sorted Ag-specific CD8 T cells in TRIZOL
(Gibco/Invitrogen, Rockville, MD) according to manufacturer’s protocol. The
cDNA was synthesized using Superscript Choice cDNA Synthesis Kit
(Gibco/Invitrogen, Rockville, MD) and an oligo(dT) primer containing a T7
promoter. The MEGAscript T7 kit (Ambion, Austin, TX) was used to amplify
cRNA from the cDNA. The cRNA was reverse transcribed with fluorescently
labeled nucleotides and hybridized to the Glyco-gene chip at the Scripps
Research Clinics Microarray Core as part of the CFG (La Jolla, CA).

In vivo CFSE proliferation assay
ST6Gal-I+/- x P14 Tg+ Thy 1.1 and ST6Gal-I-/- x P14 Tg+ Thy 1.1 mice were
sacrificed, spleens were collected, and processed to yield single cell suspensions
of 107 cells/ml in RPMI media. CD8 T cells were isolated by negative purification
using a CD8 T cell isolation kit (Miltenyi Biotec, Germany) following
manufacturer’s instructions. Briefly, 2x107 splenocytes were incubated with a
cocktail of magnetic biotin-conjugated antibodies against non-CD8 T cells,
washed, and passed through a MACS LS column placed on a MACS magnetic
separator to deplete the magnetically labeled cells, followed by three rinses with
MACS buffer. Untouched CD8 T cells were collected, washed, and counted.
These purified CD8 T cells were re-suspended at 1x107 cells/ml in PBS and
incubated with 5µM final concentration of CFSE in PBS for 3 minutes at room
temperature, mixed, and incubated for 4 more minutes. Fetal calf serum
(Hyclone, Logan, UT) was added at a final 10% concentration, mixed, and
incubated for 3 minutes, followed by addition of complete RPMI. CFSE labeledCD8 T cells from Tg WT or Tg KO mice were re-suspended in PBS, and 5x105
cells in 0.5 ml PBS were injected i.v. into naïve Thy1.2+ C57BL/6 recipient mice,
followed by infection with 2x105 PFU LCMV Armstrong i.p. the next day.
Recipient mice were sacrificed at day 3 post-infection and splenocytes were
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stained with anti-CD8 and anti-Thy1.1 antibodies, and CFSE intensity was
measured by flow cytometry.

In vitro assays
Activation and proliferation: Spleen cells were isolated from ST6Gal-I+/- x P14 Tg+
Thy 1.1 and ST6Gal-I-/- x P14 Tg+ Thy 1.1 mice. 2x105 spleen cells were
incubated with 0.01ug/ml GP33-41 peptide in 96-well plates, in triplicate. Cells
were harvested as indicated, fixed, and stained as previously described (Kalia et
al., 2010).
Vaccinia plaque assay: Plaque assays were performed on homogenized ovaries
using M2-10B4 cells, as previously described (Lutarewych et al., 1997).

Results

Dramatic changes in expression of the glycosyltransferase ST6Gal I during
memory T cell differentiation
To examine glycosyltransferase gene expression during memory T cell
differentiation, we used P14.Thy1.1 TCR transgenic CD8 T cells, specific for the
GP33-41 peptide of the LCMV envelope glycoprotein and interrogated gene
expression using the NIGMS Consortium for Glycomics (CFG) Glyco-chip that
contains probe sets to ~1800 murine and human glycosylation-related genes.
Naïve CD8 T cells were obtained directly from uninfected transgenic mice, while
Ag-specific effector and memory populations were generated following adoptive
transfer and infection of C57BL/6 Thy1.2 mice as previously described (Kaech et
al., 2002). Isolation of CD8+Thy1.1+ cells at various times post-infection yielded
pure populations of T cells with the same TCR specificity undergoing progressive
differentiation into memory cells. Gene expression profiles were analyzed and
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the results are available online (http://www.functionalglycomics.org/). Of ~50
glycosylation-specific genes that showed changes in gene expression, several
were glycosyltransferases. One glycosyltransferase, ST6Gal I, showed a greater
than 20-fold reduction in expression comparing day 8 effector cells to naïve cells
(Figure 4.1A). However, this expression increased during the transition from day
8 effector cells to day 100 memory cells, with memory cells showing an
intermediate expression compared to naïve and effector cells (Figure 4.1B).
To analyze CD8 T cell surface expression of (Siaα2-6Gal) modifications, we
used the elderberry bush derived lectin, Sambucus nigra agglutinin or SNA.
FACs analysis revealed that changes in St6gal1 gene expression were
accompanied by concomitant glyco-phenotypic changes in lectin binding (Figure
4.1B). Naïve CD8 T cells were uniformly SNAhigh, while day 8 effector CD8 T cells
were uniformly SNAlow. Interestingly, memory CD8 T cells were heterogeneous,
with the population showing both SNAhigh and SNAlow populations (Figure 4.1B).
We have previously demonstrated that unlike CD8 T cells, SNA binding remained
uniformly high on naïve resting B cells, plasma cells (PC), and germinal center
(GC) B cells following viral infection (Zeng et al., 2009). Our data supported
previously published work analyzing terminal sialylation of N-linked glycans of B
cells activated in vitro using MALDI-TOF mass spectrometry (Comelli et al.,
2006). To query whether CD4 T cells also undergo glyco-phenotypic changes
during activation and differentiation in vivo similar to CD8 T cells, we examined
SNA binding of CD4 T cell populations following viral infection. As expected,
naïve (CD44low) CD4 T cells were also uniformly SNAhigh similar to naïve CD8 T
cells and resting B cells (Figure 4.1C). However, we discovered that at day 8
following LCMV infection, CD4 T cell populations diverged, showing unique
glyco-phenotypic changes compared to other immune cell populations. Similar to
GC B cells and plasma cells, CXCR5+ T follicular helper cells at day 8 were
SNAhigh (Figure 4.1C). In contrast, the Ag-specific CD4 T cell population at day 8
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was heterogeneous with both SNAhigh and SNAlow GP61-80 specific CD4 T cells
(Figure 4.1C). Memory Ag-specific CD4 T cells were mostly SNAhigh, in contrast
to CD8 memory T cells, which were heterogenous with mostly SNAlow (~70%),
and a sub-population of SNAhigh memory CD8 T cells. Overall, CD8, CD4, and B
cell populations show unique patterns of SNA lectin binding following cell
activation in vivo. Our observations of unique SNA-binding changes among Agspecific CD4 T cell populations support and extend recent work showing that
different T helper populations show differences in ST6Gal I expression and SNA
binding (Toscano et al., 2007).
We further explored the heterogeneous nature of the memory CD8 T cell
population by examining expression of other cell markers that have been shown
to change during memory differentiation such as CD62L and 1B11, but found no
correlative binding (unpublished data). We were unable to identify any other
marker that uniquely identified these two subpopulations. To determine whether
there were any functional differences between these two memory T cell subsets,
we sorted memory CD8 T cell populations into SNAhigh or SNAlow populations,
adoptively transferred them into recipient mice, and infected these mice with
LCMV clone 13 (Figure 4.1D). Serum and PBMCs were collected from each
group, and viral titers and Ag-specific T cells were measured. While all groups of
mice that received memory T cell populations cleared virus by day 15, mice that
received SNAhigh memory CD8 T cell populations showed faster kinetics of viral
clearance and increased early proliferation compared to mice that received
SNAlow memory populations (Figure 4.1E, 1F). These data suggested that
ST6Gal I expression by CD8 T cells may promote faster viral-specific responses.

Impaired viral-specific responses in ST6Gal I-deficient mice
Since SNAhigh memory CD8 T cells showed evidence of more rapid viral specific
responses, we investigated viral specific T cell responses in ST6Gal I-/- mice.
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ST6Gal I-/- mice were generated several years ago and show mostly normal T
and B cell development, but display impaired T-dependent and T-independent
humoral responses (Hennet et al., 1998; Zeng et al., 2009). Defective B cell
responses in these mice can be rescued by genetic ablation of the Siaα2-6Gal
specific mammalian lectin CD22, a negative regulator of BCR signaling (Collins
et al., 2006; Grewal et al., 2006).
ST6Gal I-/- and C57BL/6 WT mice were infected with 2x105 pfu LCMV-Armstrong
(Figure 4.2). We measured significant impairments in the generation of LCMVspecific CD8 T cell responses, LCMV-specific CD4 T cell responses, and LCMVspecific humoral responses in ST6Gal I-/- mice at day 8 (Figure 4.2A). When we
examined Ag-specific CD8 T cells on day 8, we noted that several memory
effector precursor (MPEC) markers were more highly expressed on CD8 T cells
of ST6Gal I-/- mice, including CD127 (IL-7Rα) (Figure 4.2B). When we compared
terminal

effector

or

short-lived

effector

cell

(SLEC)

populations

(KLRG1highCD127low), we noted that this population was significantly reduced in
ST6Gal I-/- mice, whereas MPEC numbers were similar (Figure 4.2C). When we
calculated the ratio of these populations at day 8, we found that 5-10% of the
total day 8 CD8 T cells were memory precursors in WT mice, while in ST6Gal I-/mice 40-45% of total day 8 CD8 T cells were memory precursors (Figure 4.2C).
Consistent with the higher ratio of memory precursors, measurement of Agspecific CD8 and CD4 T cell populations at memory revealed that memory T cell
generation was not impaired in ST6Gal I-/- mice, despite reduced T cell
expansion at day 8 (Figure 4.2D). Examination of functional memory by analysis
of re-call responses following infection of immune WT and ST6Gal I-/- mice with
recombinant Vaccinia expressing GP33 (VV-GP33) showed that ST6Gal I-/- mice
generated similar numbers at day 3 of re-call and showed similar viral control
(Figure 4.2E). Taken together, the loss of ST6Gal I significantly impaired early
viral-specific T cell responses, however a greater proportion of the CD8 T cell
response was programmed to become functional memory T cells.
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T-bet regulates St6gal1 expression
Our discovery that terminal effector or SLEC expansion was reduced in ST6Gal I
-/-

mice (Figure 4.2C) prodded us to examine gene expression in effector subsets

since our earlier studies analyzing total day 8 effectors potentially obscured
differences in recently identified SLEC and MPEC subset populations (Joshi et
al., 2007) (Figure 4.1). Comparison of KLRG1highIL-7Rlow (SLEC) to KLRG1lowIL7Rhigh (MPEC) CD8 T cells at day 6-8 revealed that MPECs have higher
expression of St6gal1 (Figure 4.3A). However, this difference in expression may
be due to greater down-regulation of St6gal1 in SLEC. Since several
transcriptional regulators have recently been identified as differentially expressed
in effector subsets, and high levels of certain transcriptional regulators (eg. T-bet,
Blimp-1) promote effector CD8 T cell terminal differentiation (Rutishauser and
Kaech, 2010), we queried whether loss of T-bet expression influenced St6gal1
expression.
T-bet expression increases dramatically upon activation of naive T cells, with
higher expression in SLECs compared to MPECs (Kalia et al., 2010; Pipkin et al.,
2010; Rutishauser and Kaech, 2010). Examination of T-bet-/- SLECs compared to
MPECs revealed similar expression of St6gal1 (Figure 4.3B left panel). Thus, Tbet expression was required for differential expression of St6gal1 in SLEC versus
MPEC populations. Further, comparing St6gal1 expression in WT MPECs versus
T-bet-/- MPECs, T-bet-/- memory precursors expressed ~12-fold higher St6gal1,
while T-bet-/- SLEC expressed ~80-fold higher St6gal1 compared to WT SLEC
(Figure 4.3B middle and right panel). These data provided evidence that T-bet
expression regulates the expression St6gal1, where loss of T-bet expression
results in increased St6gal1 expression in effector subsets. However, we do not
yet know if this repression by T-bet is direct or indirect, for example if T-bet
transcriptionally repressed St6gal1 expression.
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Interestingly, day 8 TFH cells remained SNAhigh (Figure 4.1C) and this population
of T cells has been shown to express Bcl-6, the mutually antagonistic
transcriptional repressor of Blimp-1 and T-bet (Johnston et al., 2009; Rutishauser
and Kaech, 2010). ST6Gal I-/- mice showed more disorganized T cell zones in
splenic B cell follicles at day 8 post-infection, with variably dispersed CD4 T cells
(Figure 4.4).

Impaired CD8 T cell expansion is cell intrinsic
Since we observed reduced expansion of CD8 T cells in ST6Gal I-/- mice (Figure
2A), but also reductions in other viral-specific lymphocyte populations, such as
CD4 T cells and B cells which influence CD8 T cell expansion (Crawford et al.,
2006), we were unsure whether defective CD8 T cell expansion in these mice
was cell autonomous. To understand if reduced expansion of CD8 T cells lacking
ST6Gal I was due to cell intrinsic defects, we generated transgenic P14xST6Gal
I-/- mice (Figure 4.5A). CD8 T cells from these transgenic mice were adoptively
transferred into recipient C57BL/6 Thy1.2 mice and Ag-specific responses were
evaluated.

As shown in Figure 4.5B, we observed significantly reduced

expansion at day 8 of Ag-specific CD8 T cells that lacked ST6Gal I, with a larger
fraction of the endogenous/host response contributing to the DbGP33-41 CD8
specific response. To further examine this, we performed a competitive in vivo
assay and adoptively transferred equal numbers of P14xST6Gal I+/- and
P14xST6Gal I-/- CD8 T cells into the same C57BL/6.PL (Thy1.1) recipient mice
(Figure 4.5C).

As before, Ag-specific CD8 T cells that expressed ST6Gal I

showed greater expansion at day 8, with significantly higher frequencies
compared to CD8 T cells that did not express ST6Gal I. These data provided
evidence that ST6Gal I expression by CD8 T cells was required for optimal CD8
T cell expansion in vivo.
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These observations of reduced numbers of Ag-specific CD8 T cells at day 8 did
not distinguish whether the reduced numbers of ST6Gal I-/- CD8 T cells were due
to reduced proliferation or increased apoptosis in vivo. To determine whether
reduced expansion was due to decreased proliferation, P14xST6Gal I+/- and
P14xST6Gal I-/- CD8 T cells were purified and CFSE labeled. These labeled cells
were then adoptively transferred into C57BL/6 recipient mice, and CFSE dilution
was measured at day 3 post-infection with LCMV. As shown in Figure 4.5D, CD8
T cells that lacked expression of ST6Gal I, showed diminished proliferation, with
a greater number of undivided CD8 T cells. Taken together, these data show that
loss of ST6Gal I expression by CD8 T cells resulted in reduced expansion due to
impaired CD8 T cell proliferation.

Similar recruitment and T cell activation, but delayed IL-2Rα expression of
ST6Gal I-/- CD8 T cells
Since our data showed that ST6Gal I deficient CD8 T cells trailed in division of
ST6Gal I expressing CD8 T cells following antigen exposure, we examined
proliferation in more detail. We hypothesized that the reduced proliferation could
be due to a delay in recruitment of ST6Gal I-/- CD8 T cells into the viral specific
response. Loss of expression of ST6Gal I by CD8 T cells results in a reduction of
sialylated biantennary N-glycans, and may lead to differential recognition of T
cells by antigen-presenting cells expressing glycan binding proteins (GBPs) that
recognize sialylated N-glycans (Comelli et al., 2006). Examples of GBPs that
bind sialic acids include CD22 (aka siglec-2) and CD169 (aka siglec-1,
sialoadhesin, or MOMA-1), which are expressed by B cells and marginal zone
macrophages, respectively; both CD22+ B cells and CD169+ macrophages have
been suggested to play a role in T cell activation (Collins et al., 2004; Junt et al.,
2007; Oehen et al., 2002; Oetke et al., 2006; van den Berg et al., 1992). Since
several studies have suggested that ST6Gal I expression by tumor cells
influences cell motility and migration, we hypothesized that loss of ST6Gal I
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expression was inhibiting interaction with CD169+ expressing marginal zone
macrophages or other siglec-expressing APCs in vivo, leading to reduced
recruitment of ST6Gal I-/- CD8 T cells into the immune response (Junt et al.,
2007; Kumamoto et al., 2004; Qian et al., 2009). The magnitude of an adaptive
immune response is regulated by the number of cells that are recruited from the
naïve repertoire, and the burst size of participating clones (van Heijst et al.,
2009). If recruitment of naïve CD8 T cells was impaired by the loss of ST6Gal I,
this would be reflected in a reduced percentage of transferred T cells becoming
initially activated.

We examined early T cell activation in vivo. Here we adoptively transferred
P14xST6Gal I+/- versus P14xST6Gal I-/- CD8 T cells into WT recipient mice,
monitored CD8 T cell expansion and surface expression during the first hours
and days of viral infection, and focused on early activation markers CD69 and
CD25. CD69 expression comes up rapidly on T cells following TCR stimulation,
while expression of CD25, the α chain of the high affinity IL-2R, is regulated both
by TCR signaling and IL-2/IL-2R signaling via STAT5 (Malek TR, 2008). We
included analysis of the IL-2R because of its pivotal role in T cell proliferation, its
recently recognized role in memory T cell programming, and evidence that this
receptor is a substrate for ST6Gal I (Leonard et al., 1983; Malek et al., 1995). As
shown in Figure 4.6A, by day 5 Ag-specific CD8 T cells expressing ST6Gal I
have increased ~700-fold, and consistent with earlier data, Ag-specific CD8 T
cells lacking expression of ST6Gal I show significantly less expansion. However,
when we examined T cell activation and recruitment into the immune response,
we observed that in the first 12 hours, activation of the transferred CD8 T cells
occurred similarly, with identical kinetics for CD69 and CD25 (Figure 4.6B, C left
panels). By 24 hours post-infection, CD69 expression is high on all transferred
CD8 T cells regardless of expression of ST6Gal I (Figure 4.6B). Similar results
were seen analyzing CD44 and CD62L (unpublished data). This data provided
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strong evidence that recruitment and activation of ST6Gal I-/- Ag-specific CD8 T
cells was not impaired. However, examination of CD25 expression revealed that
surface expression of the IL-2Rα chain was delayed from 12-24 hrs in Agspecific CD8 T cells that did not express ST6Gal I (Figure 4.6C, right panel).
Thus, these data suggested that ST6Gal I expression by naïve CD8 T cells
promoted rapid and prolonged IL-2Rα expression, which would contribute to
early and more extensive proliferation of terminal effectors (Kalia et al., 2010).

IL-2/IL-2R signaling and surface expression is impaired in ST6Gal I-/- CD8 T
cells
CD25 (IL-2Rα) expression is regulated by signals through both the TCR and the
IL-2R, so defects in either TCR signaling, IL-2R signaling, or both, may contribute
to impaired surface expression of this receptor chain. We observed no
differences in TCR stimulation in vivo comparing ST6Gal I-expressing and
ST6Gal I-deficient Ag-specific CD8 T cells during the first 24 hours of viral
infection (Figure 4.6B). CD25 expression was similar in the initial 12 hours of viral
infection, but was different in the ensuing 12-24 hours post-infection (Figure
4.6C). Previous reports have demonstrated that IL-2 splenic concentrations peak
within the first day of LCMV infection (Kalia et al., 2010). Based on these data,
we formulated a new hypothesis where we considered TCR signaling resulted in
normal CD25 expression by ST6Gal I-/- CD8 T cells, however IL-2/IL-2R signaling
was impaired, resulting in diminished CD25 expression.
To test this, we examined in vitro proliferation of P14xST6Gal I+/- versus
P14xST6Gal I-/- CD8 T cells following GP33-41 peptide stimulation (Figure 4.7A).
Cell clusters were smaller in P14xST6Gal I-/- CD8 T and we confirmed our
observation of reduced proliferation of these cells (Figure 4.7A). Peptide
stimulated Ag-specific CD8 T cells made similar amounts of IL-2, TNFa, and
IFNg, similar to results we found in vivo (unpublished data). Cell viability dropped
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significantly during the first day of in vitro culture of both WT and ST6Gal I-/- CD8
T cells, and ST6Gal I-/- CD8 T cells showing significantly reduced viability (Figure
4.7B).
We then examined early activation, comparing expression of CD25 and
phosphorylated

STAT5

(pSTAT5).

We

stimulated

P14xST6Gal

I+/-

or

P14xST6Gal I-/- CD8 T with GP33-41 peptide and IL-2, or IL-2 only. Addition of
IL-2 to the culture conditions significantly increased viability of both WT and
ST6Gal I-/- CD8 T cells and was dose-dependent (unpublished data). As shown
in Figure 7C, in the presence of GP33-41 peptide, both P14xST6Gal I+/- and
P14xST6Gal I-/- CD8 T showed similarly high percentages of CD25high cells,
although total MFI was reduced for ST6Gal I-/- CD8 T cells. ST6Gal I-/- CD8 T
cells showed no difference in pSTAT5 following peptide stimulation (Figure
4.7D). CD8 T cells cultured with IL-2 only showed lower expression of CD25
compared to peptide stimulated cells (Figure 4.7C). However, analysis of ST6Gal
I-/- CD8 T cells revealed that these cells had fewer CD25high cells and lower
pSTAT5 compared to ST6Gal I+/- CD8 T cells (Figure 4.7C-D). These data
provided evidence that IL-2/IL-2R signaling was impaired in ST6Gal I-/- CD8 T
cells, inhibiting IL-2Rα expression.
Taken together, our data suggests that CD8 T cells regulate ST6Gal I to promote
expression of IL-2Rα following IL-2/IL-2R signaling, leading to more rapid
expression of the high affinity IL-2 receptor on Ag-specific CD8 T cells. This
earlier and prolonged expression of IL-2Rα by naïve CD8 T cells appears to
favor proliferation and differentiation of short-lived effectors. Our data provides
the first evidence that a specific carbohydrate modification, the addition of α2,6linked N-glycans, appears to fine-tune responses through the IL-2R, thus
amplifying early T cell expansion and influencing cell fate differentiation.
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Discussion
Essentially all mammalian cells are covered with a dense, complex array of
oligosaccharides or sugars termed the glycocalyx, through which the cell
interacts with its environment (Varki, 2008). Many cell surface glycoprotein
receptors have significant numbers of N-glycan sites, and recent work has shown
that both the complexity and numbers of N-glycans can regulate cell proliferation
and differentiation (Lau et al., 2007). Sialic acids are typically found on the
outermost end of glycan chains, and given their wide distribution, can modulate a
variety of normal and pathological processes (Varki, 2008). N-linked sialylation in
particular, has been suggested to play a significant role in tumor biology,
modulating growth and differentiation of carcinomas (Hedlund et al., 2008).
Following T cell activation in vivo, T cells undergo an exponential growth phase,
characterized by gene expression changes and glyco-phenotypic changes
(Kaech et al., 2002; Murali-Krishna et al., 1998; Onami et al., 2002). These cells
differentiate into effector cells, and a subset become memory T cells (Joshi et al.,
2007).

We

discovered

using

a

microarray

analysis

that

ST6Gal

I,

sialyltransferase expressed in the Golgi that is responsible for α2,6-sialylation on
N-glycans, was differentially expressed during memory CD8 T cell differentiation
and showed concomitant changes in surface SNA lectin binding (Figure 4.1).
Moreover, we found that T cells expressing St6gal1 showed more proliferative
capacity, while those lacking St6gal1 expression divided less and showed slower
growth (Figures 4.2 and 4.5). T-bet repressed expression of St6gal1, and lower
expression of St6gal1 was observed in terminally differentiated effector
populations, or SLECs (Figure 4.3). Interestingly, tumors that lacked expression
of St6gal1 also showed more terminal differentiation (Hedlund et al., 2008). In
contrast, memory precursor and memory T cells, which retain their stem cell-like
proliferative capacity, have higher expression of St6gal1 compared to effector T
cells (Figure 4.1 and 4.3). Similarly, tumors expressing St6gal1 are less
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differentiated and increased St6gal1 expression correlated with poor prognosis
(Hedlund et al., 2008).
IL-2 is tightly regulated due to its potent stimulatory properties, and is typically
produced by recently activated T cells, acting in an autocrine or paracrine fashion
(Letourneau et al., 2010). CD25 has recently been suggested to play an
unanticipated role in the regulation of IL-2 homeostasis (Letourneau et al., 2010).
Most IL-2 production in vivo occurs in secondary lymphoid organs and evidence
suggests it is likely consumed there by proliferating CD25/IL-2Rα+ T cells
(Letourneau et al., 2010). Prolonged CD25/IL-2Rα expression on virus-specific
CD8 T cells has been shown to favor the differentiation of terminal effectors
(Kalia et al., 2010; Pipkin et al., 2010). CD25high CD8 T cells show more
extensive early proliferation in vivo, while CD8 T cells with lower expression of
CD25 are relatively less sensitive to IL-2, and give rise to long-lived memory cells
(Kalia et al., 2010). In ST6Gal I-/- mice, we observed that expansion of SLECs
was compromised, while memory precursor development was enhanced (Figure
4.2). CD25/IL-2Ra expression was delayed on ST6Gal I-/- CD8 T cells and we
present evidence that the delay in surface expression of the high affinity IL-2Rα
on activated ST6Gal I-/- CD8 T cells was likely attributable to defective IL-2/IL-2R
induced expression of IL-2Ra (Figure 4.6 and 4.7). Thus, early proliferation was
reduced. However, a greater proportion of the ST6Gal I-/- CD8 T cell effector
population was memory precursors (Figure 4.2). Thus, despite lower overall CD8
T cell expansion, function and number of memory T cells was comparable in
ST6Gal I-/- mice. Thus St6gal1 expression is not required for memory T cell
differentiation, but is required for optimal proliferation of terminally differentiated
effectors or SLECs.
St6gal1 expression is significantly down-regulated following activation of CD8 T
cell populations compared to naïve CD8 T cells, and we speculate based on our
data that for naïve CD8 T cells, the function of high St6gal1 expression is to
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amplify signals through the IL-2 receptor, promoting greater proliferation. In
contrast, activated CD8 T cells may limit this amplification of IL-2 signals by
reducing expression of this sialyltransferase and consequently altering N-linked
sialylation of ST6Gal I glycoprotein substrates. The α and β chains of IL-2R have
been shown to be N-glycosylated and sialylated, and changes in glycosylation
may change competition for this cytokine receptor in its heterodimeric (βγ) or
heterotrimeric (αβγ) forms (Asao et al., 1990; Leonard et al., 1983; Opdenakker
et al., 1995). Glycosylation of cytokines or cytokine receptors influences specific
biological activities, with several studies asserting that glycosylation attenuates
cytokine activity (Opdenakker et al., 1995). Since recent work suggests that
sustained IL-2R signaling drives terminal effector differentiation, the reduction in
St6gal1 expression may limit these signals, switching to the promotion of
functional long-lived memory differentiation. These memory precursors may
undergo less proliferation compared to their shorter-lived counterparts.
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Figure 4. 1. Dramatic changes in expression of the glycosyltransferase
ST6Gal I during memory T cell differentiation.
1x106 Thy1.1+ DbGP33-41 specific transgenic splenocytes were adoptively
transferred into C57BL/6 mice and these mice were infected with 2x105 pfu
LCMV Armstrong i.p. CD8 T cell populations were then enriched from
splenocytes from naïve transgenic mice (day 0) or day 8, day 15, day 22, or day
100 post-infection chimeric mice by depletion with MHC class II and CD4 beads.
Thy1.1+ CD8+ T cells were then FACS sorted to greater than 94% purity and
mRNA was isolated and linearly amplified and assayed by the Glyco-Gene chip.
A, Summary of fold change of specific genes expression in CD8 T cell at day 8
compared to those in naïve CD8 T cell. The function of ST6Gal I is to catalyze
the addition of α2,6 sialic acids to galactose. SNA lectin binds α2,6Galβ14GlcNAc. B, Time-course of ST6Gal I gene expression during CD8 T cell
activation in vivo shows dramatically reduced expression. Right panel showed
the SNA lectin binding of CD8 T cell populations. Splenocytes from uninfected
(naïve) Tg P14 mice, or P14 x Thy1.1 chimeras on day 8 or day 150 postinfection with 2x105 pfu LCMV-Armstrong i.p. were stained with DbGP33-41
tetramer, CD8 mAb, and SNA lectin. Gating on antigen-specific CD8 T cells
reveals high staining of SNA on naïve CD8 T cells (SNAhigh), low binding on day
8 effector CD8 T cells (SNAlow), and both populations among memory cells,
SNAhigh and SNAlow. C, SNA lectin bingding of CD4 T cell populations.
Splenocytes from uninfected (naïve) mice, or C57BL/6 mice on day 8 or day 200
post-infection with 2x105 pfu LCMV-Armstrong i.p. were harvested and
stimulated with GP61-80 for 4-5 hours, stained with CD44, or CXCR5, or IFNγ,
CD4 mAb, and SNA lectin. D, Cartoons showing experimental procedure of recall
responses of SNAhigh versus SNAlow binding memory CD8 T cells. Memory
Thy1.1+ CD8+ T cells were sorted for SNAhigh versus SNAlow binding (greater than
95% purity, not shown) and equal numbers of SNAhigh, SNAlow, or total antigenspecific CD8 T cells were adoptively transferred into naïve C57BL/6 mice and
123

mice were infected with 2x106 pfu LCMV clone 13 i.v. Control mice received no
cells. On indicated days, mice were bled to obtain serum to assay viremia and
PBMCs to assay T cell expansion. On day 5 and day 8, mice that received
SNAhigh memory CD8 T cells showed lower viremia. E, Higher T cell expansion
compared to mice receiving SNAlow memory CD8 T cells.
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Figure 4. 2. Impaired viral-specific responses in ST6Gal I-deficient mice.
C57BL/6 wildtype or ST6Gal I null mice were infected with 2x105 pfu LCMV
Armstrong i.p. Single cell suspensions of the spleen were processed and stained
with antibodies as indicated, plasma cells gating on CD138+B220+cells, germinal
center (GC) B cells gating on PNAhigh Fas+ cell population of gated IgDlowB220+
cells. ELISPOT assay was used to determine the numbers of LCMV-specific IgM
and IgG ASCs. On day 8 p.i. A, Total numbers of T and B cells as indicated were
enumerated. B, Histogram overlay of indicated antibodies binding of DbGP3341CD8

+

T cells. Blue histogram shows B6, and red histogram shows ST6Gal I-/-.

Bar graphs show mean fluorescence of indicated antibodies binding in both
groups of mice. C. FACS analysis of SLEC and MPEC in same mice. Contour
dot plot shows SLEC (KLRG1high IL7low) and MPEC (KLRG1low IL-7high)
populations. Total numbers of SLEC and MPEC and their ratios were
enumerated in bar graphs. D, Kinetics of total numbers of antigen-specific CD8
and CD4 T cells measured by FACS or ICS on indicated days. E, total numbers
of antigen-specific CD8 T cell in Memory and recall response. Viral titer in the
ovaries on day 3 mice challenged intravenously with 2 x 106 PFU vaccinia
expressing the GP33-41 peptide of the LCMV viral protein. Grey bar shows naïve
mice; black bars are i.p. B6; and white bars are i.p. ST6Gal I-/-. Data from n=6-12
mice.
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Figure 4. 3. T-bet regulates St6gal1 expression.
Gene expression analysis was performed on day 6 and 8 p.i. with LCMV
Armstrong pooled WT and T-bet null effector cells gating on CD8+ and tetramer
DbGP33-41 population by microarray. Fold change of St6gal1 expression in WT
MPEC compared to that in WT SLEC (A). From left to right: T-bet-/- SLEC
compared to T-bet-/-MPEC, T-bet-/- MPEC to WT MPEC, and T-bet-/- SLEC to WT
SLEC (B).
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Figure 4. 4. Disrupted B cell follicle in ST6Gal I null mice following LCMV
infection.
Mice were infected with LCMV intraperitoneally or remained uninfected, and on
day 8 p.i., spleens were isolated and frozen for immunofluorescence staining
using B cell follicle marker. B220 in red and CD4 or ER-TR7 in green.
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Figure 4. 5. Impaired CD8 T cell expansion is cell intrinsic.
P14 TCR transgenic mice congenic for Thy1.1 were bred to ST6Gal I null mice.
A, Dot plot of splenocytes from ST6Gal I+/-xP14 and ST6Gal I-/-xP14 littermates
labeled with CD8, DbGP33-41 MHC tetramer, and SNA lectin. 1x106 splenocytes
from WT and ST6Gal I-/- TCR transgenic splenocytes were singly-(B) or mixed in
a 1:1 ratio and co-transferred (C) into non-transgenic naïve C57BL/6 mice by tail
i.v. injection and the recipient mice were infected with LCMV Armstrong the
following day. At day 8 p.i., total number of transferred (donor) cells were
quantified in the spleens of recipient mice by flow cytometry. Bar graphs show
n=7 for WT and n=11 for KO for single transfer (middle panel) and n=5 fo WT
and n=5 for KO for co-transfer (lower panel) D, 5x105 WT and ST6Gal I-/- TCR
trangenic CD8 T cells were purified and labeled with CFSE and transferred into
recipient C57BL/6 non-transgenic mice by tail i.v. injection. The following day, the
recipient mice were infected with 2x105 pfu LCMV Armstrong i.p. or left
uninfected. On day 3 p.i. CFSE intensity of LCMV antigen-specific CD8 T cells
was quantitated by flow cytometry. Bar graphs represent n=5 for WT and n=6 for
KO.
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Figure 4. 6. Similar recruitment and T cell activation, but delayed IL-2Rα
expression of ST6Gal I-/- CD8 T cells.
1x105 splenocytes from ST6Gal I+/-xP14 wildtype or ST6Gal I-/- xP14 TCR
transgenic splenocytes were intravenously transferred into naïve C57BL/6 mice
and the recipient mice were intravenously infected with LCMV Armstrong 4 hours
later after transfer. Spleen cells were isolated and stained with antibodies on
indicated time-points and analyzed by FACS. A, the proportion of donor CD8
Tcells was showed in Contour dot plot and quantified in bar graphs. The linear
kinetics of the percent of donor CD8 T cells expressing elevated CD69 (B) and
CD25 (C) in spleen of both groups of mice was measured by FACS analysis.
Data from n=3-6 mice.
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Figure 4. 7. IL-2/IL-2R signaling and surface expression is impaired in
ST6Gal I-/- CD8 T cells.
2 x 105 splenocytes from ST6Gal I+/-xP14 wildtype or ST6Gal I-/- xP14 TCR
transgenic mice were transferred to 96-well plate and incubated with GP33-41
(0.01µg/ml) peptide at 37 oC. A, Spleen cells clustered after 2 days incubation
with peptide. Photos are taken under light microscope at 10x magnification. B, P
roliferative response of spleen cells after incubation with GP33-41 at day 1, 2, 3.
Viable cells from single or pooled from triplicate wells were counted and
measured by FACS for live cell percent. For GP33-41+ IL-2 group, after 4 hours
incubation with peptide, cells were transferred to another plate and washed
peptide away with 10%RPMI 1640. Recombinant IL-2 was added to the wells at
a concentration of 10000 U/ml. Cells incubated for another 20 hours and
intracellularly stained with CD8, CD25 (C), and pSTAT5 (D) antibodies. For IL-2
only group, recombinant IL-2 was added from the beginning. Cells incubated for
24 hours, stained with antibodies and analyzed by FACS. Data are
representative of two independent experiments.
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As one of the most abundant post-translational modifications of peoteins,
glycosylation can impact cellular signal transduction and functionality (Ohtsubo
and Marth, 2006; Rudd et al., 2001). Glyco-phenotypic changes during immune
responses have been described for decades (Galvan et al., 1998a; London and
Horton, 1980; Onami et al., 2002) . However, their functional relevance is still
unclear. ST6Gal I is a glycosyltransferase that catalyze the addition of sialic acid
to galactose via α2,6-linkage to generate the Siaα2,6 structure (Hennet et al.,
1998). This enzyme is highly expressed on B and T lymphocytes (Hennet et al.,
1998). However, the role of this enzyme in adaptive immunity during a viral
infection remains largely unexplored. In this study, we comprehensively
interrogate the role of ST6Gal I in viral specific T and B cell responses. We also
examined the pathogenic outcome in mice loss of this enzyme.

The generation of Influenza-specific humoral responses is impaired in
ST6Gal I-deficient mice
We observed that SNA lectin binding, which indicate ST6Gal I expression or
activity, remains at high levels on naïve B cells, plasma blasts, and germinal
center B cells following viral infection (Figure 2.1). To understand the functional
relevance of ST6Gal I expression in B cell immunity, we infected ST6Gal I-/- mice
with influenza virus. We demonstrated that the absence of ST6Gal I results in
decreased early influenza specific IgM and IgG levels in the serum, as well as
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defective generation of influenza specific antibody secreting cells (Figure 2.2).
These impairments are not due to reduced viral load or antigen availability in
these mice as influenza virus replicates similarly in the lungs (Figure 2.4). In
contrast to impairments in the generation of acute antiviral humoral responses,
ST6Gal I-/- mice are able to establish antiviral humoral memory, with high levels
of IgG antibodies after day 14 p.i. (Figure 2.2, 2.6).
To determine whether the observed impairment of viral specific humoral
responses were B cell intrinsic, we adoptively transferred purified B cells with or
without ST6Gal I into B cell deficient mice and infected with influenza virus. The
viral specific IgM response was significantly reduced in mice that received
ST6Gal I-/- B cells, whereas the viral specific IgG response was comparable
compared to mice that received ST6Gal I+/+ B cells (Figure 2.7). These results
indicate the expression of ST6Gal I by B cells, at least partially, is required for
optimal antiviral humoral responses.

ST6Gal I deficiency results in altered sialylation of IgG and IgA, and
promotes IgA mesengial deposition following influenza infection
Previously, we found that ST6Gal I-/- mice demonstrated impairments in the
generation of early antiviral specific IgM and IgG responses (Figure 2.2),
whereas humoral immunity was normally established (Figure 2.6). When we
analyzed the influenza specific IgA responses, paradoxically, we discovered that
although ST6Gal I-/- mice showed impaired early influenza specific IgA
responses, by memory time-points the levels of total IgA, and influenza specific
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IgA were elevated in the serum of immune ST6Gal I-/- mice following influenza
infection (Figure 3.1).
As increased IgA levels in serum is highly correlated with the occurrence of a
human disease, IgA nephropathy (D'Amico, 2004). We then examined whether
evidence of glomerulonephritis developed in immune ST6Gal I-/- mice following
influenza infection. We found that although immune ST6Gal I-/- mice displayed
normal gross pathology of the kidneys (Figure 3.1, Table 3.1), they showed
increased IgG and IgA deposition in the kidney glomeruli (Figure 3.2, 3.5), which
is a hallmark of IgA nephritis (D'Amico, 2004). We noted that aberrant
glycosylation of antibody has been proposed to affect the development of IgA
nephritis (Novak et al., 2008). We therefore analyzed the glycosylation of IgG
and IgA. We found that ST6Gal I-/- mice showed abnormal glycosylation in the Nglycans of both IgG and IgA, with a complete loss of terminal sialylation of Nglycans in IgG, and reductions in sialylated N-glycans in IgA (Figure 3.3, 3.4).
Taken together, these data suggested that ST6Gal I deficiency, together with
influenza infection, may initiate IgA nephritis.

ST6Gal I promotes rapid IL-2Rα surface expression, increasing early
proliferation of terminal effector CD8 cells
We have demonstrated that SNA lectin binding remained high on B cells during
activation and differentiation (Figure 2.1). In contrast, we discovered that ST6Gal
I was differentially expressed during CD8 T cell differentiation, associated with
changes in SNA binding accordingly (Figure 4.1). To investigate the functional
significance of this differential regulation of ST6Gal I, we infected ST6Gal I-/- mice
and demonstrated significant impairments in the generation of viral-specific T and
B cell responses in ST6Gal I-/- mice (Figure 4.2). To ascertain whether reduced
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ST6Gal I-/- CD8 T cell expansion was due to cell intrinsic defects, we adoptively
transferred CD8 T cell with or without ST6Gal I into recipient mice and viralspecific responses were measured. We found that ST6Gal I-/- effector CD8 T cell
displayed defective expansion and diminished proliferation (Figure 4.2, 4.5),
indicating that lack of ST6Gal I by CD8 T cells led to defective expansion due to
impaired CD8 T cell proliferation. Moreover, ST6Gal I-/- CD8 T cells skewed
towards memory precursor cells, while terminal effector cell proliferation was
dampened (Figure 4.2). When we examined the proliferation in more detail, we
found that IL-2Rα surface expression was delayed in vivo on ST6Gal I-/- CD8 T
cells (Figure 4.6). We provide evidence of this delayed IL-2Rα expression is
likely due to defective IL-2/IL-2R signaling (Figure 4.7). These studies indicate
that the intrinsic expression of ST6Gal I promotes the rapid surface expression of
IL-2Rα to elevate early proliferation of terminal effector CD8 T cells during viral
infection.
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